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Prescription drug abuse is a continuing problem in the United States.  Educating 
physicians on issues related to prescription drug abuse is a key factor in preventing and 
treating this problem. High variability has been found in substance abuse terminology in 
the literature, textbooks, and FDA-approved product labeling.  This dissertation describes 
a survey study designed to address how the variability in substance abuse terminology, 
specifically package inserts, affects the prescribing decisions made by physicians. 
 xiii
A random sample of 1008 physicians currently licensed and residing in the 
Commonwealth of Virginia received a letter of explanation, a self-administered 
questionnaire, and a follow-up reminder and thank you.  To increase response rate, a 
second questionnaire was sent to non-responders.  Prescribing decisions made by 
physicians were measured as three variables: comfort level with a prior physician’s 
choice, likelihood of refilling the prescription, and likelihood of prescribing a drug or 
drug class as the first physician seeing a particular patient.  Physicians were presented 
with four case scenarios which included package insert information and selected patient 
characteristics.  Other factors affecting physicians’ decisions in prescribing controlled 
substances include ideas about addiction, and characteristics of the physician, patient, 
disease state, and drug.  The patient case scenarios and other items on the questionnaire 
addressed these covariates. 
 Based on the number of deliverable questionnaires returned and included in 
analysis, the response rate was 32.3%.  More physicians associated abuse, craving, drug-
seeking behavior, psychological dependence, and withdrawal with addiction than with 
drug dependence, while more physicians felt that physical dependence and tolerance were 
necessary for drug dependence.  The most frequently used sources for drug information 
were the Physicians’ Desk Reference (PDR), package inserts, and pharmacists. 
 xiv
Four linear regression models were created for physician prescribing decisions.  
Physician, patient and package insert characteristics were all significant (p<0.05).  
Interaction terms for type of pain and history of substance abuse were also significant, 
indicating that the importance of substance abuse history is dependent on the type of pain 
being treated. 
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1 Introduction 
CHAPTER 1 
Introduction 
Overview of the Document 
This dissertation describes a survey research study designed to investigate how 
the variability in substance abuse and dependence terminology in package inserts affects 
prescribing decisions made by physicians, explore how physicians define “drug 
dependence” and “drug addiction,” and identify the sources used by physicians for drug 
information.  This chapter provides background information on prescription drug abuse in 
the United States, the history of substance abuse and dependence terminology, and 
factors affecting physician prescribing decisions.  Chapter 2 presents a more in depth 
overview of the literature of terminology, package inserts, and physician surveys.  
Chapter 3 provides details on a preliminary study of package insert information 
specifically on substance abuse and dependence information.  Chapter 4 describes the 
methodology used for this survey study, Chapter 5 portrays its results, and Chapter 6 
summarizes and discusses conclusions from the study. 
Prescription Drug Abuse in the United States 
Dr. Alan Leshner, the Director at the National Institute on Drug Abuse (NIDA), 
stated in a July 2001 research report that “abuse of prescription drugs remains a serious 
public health concern.” (National Institute of Drug Abuse (NIDA), 2001). 
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Looking specifically at non-medical use of prescription drugs, four categories are 
examined by the National Survey on Drug Use and Health (NSDUH).  They are: pain 
relievers, stimulants, tranquilizers, and sedatives.  Non-medical use is classified as intake 
of a prescription medication that is not prescribed for the person using it or use only for 
the feeling that is caused by the drug.  Table 1.1 shows, for 1990 and 2001, the number of 
people using these four categories of prescription drugs for non-medical use. 
 
Table 1.1  New non-medical users of prescription drugs 
Category 1990 2001
Pain relievers 628,000 2,400,000
Stimulants 270,000 808,000
Tranquilizers 373,000 1,100,000
Sedatives <300,000 <300,000
 
 
There is a notable increase in initiation of use of prescription pain relievers, 
stimulants, and tranquilizers over the 11 years spanning 1990 and 2001.  The number of 
sedative initiates, however, has remained under 300,000 since 1981.  Peak use of 
sedatives was at 638,000 new users in 1977, then steadily dropped off and remained 
fairly stable, with a slow but steady rise from 111,000 in 1995 to 175,000 in 2000 (OAS, 
2003).  Clearly, while sedatives have not proven to be as popular for new users, 
tranquilizers, stimulants, and prescription pain relievers have shown large increases in the 
estimated number of new users over the 11 years spanning 1990 to 2001.  
From 2002 to 2004, first time non-medical use of pain relievers remained steady 
at about 2.4 million, tranquilizers at about 1.2 million, stimulants remained in the 
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700,000’s, and sedatives continue to remain under 300,000.  Data collected before 2002 
cannot be compared to data collected after 2002 because of methodology changes, 
making trend analysis for recent years unreliable.  Several more years of data are needed 
to determine whether any trend is present.  
Overall, lifetime non-medical use of psychotherapeutics increased significantly 
from 32.4 million to 36.0 million from 2000 to 2001 (p<0.01) (OAS, 2001).  The increase 
in past-year prevalence, from 3.9% (8.76 million) to 4.9% (11.10 million), and the 
increase in past-month prevalence, from 1.7% (3.85 million) to 2.1% (4.81 million) was 
also significant (p<0.01) (OAS 2001).  From 2002 to 2004, lifetime non-medical use of 
psychotherapeutics increased from 46.8 million to 48.0 million, and lifetime non-medical 
use of pain relievers increased from 29.6 to 31.8 million users (p<0.05) (OAS, 2004).  
Past-year prevalence has remained steady at about 14.6 million users, or about 6.2% of 
the population (OAS, 2004).  Past-month prevalence, a measure of current use, has also 
remained steady, at about 6 million or 2.5% of the population (OAS, 2004).  
Some may argue that drugs like heroin pose a much larger problem than abuse of 
prescription drugs.  On January 21, 2005, the Substance Abuse and Mental Health 
Services Administration (SAMHSA) released a new report based on data collected from 
the NSDUH in 2002 and 2003.  This report was comparing non-medical use of 
oxycodone to heroin use.  From 2002 to 2003, the prevalence of lifetime non-medical use 
of oxycodone increased from 11.8 million to 13.7 million users, from 5.0 to 5.8%.  
Heroin use, however, remained steady at 1.6% prevalence of lifetime use (OAS 2005).  
This suggests that people may be turning to prescription drugs as an alternative to illicit 
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drug use, although further data are needed to determine whether or not this is an 
incidental phenomenon or a trend over time.  Further evidence supporting this theory was 
reported in a recent publication from NIDA, stating that while the abuse of some drugs 
such as LSD (lysergic acid diethylamide) and Ecstasy fell, the lifetime abuse of 
prescription medications, particularly narcotic painkillers, has significantly increased 
from 2002 to 2003.  The young adult age group (18-25 years) showed a 15% increase in 
lifetime and past-month non-medical use of pain relievers (OAS, 2004). 
Whether or not the increasing trends in the prevalence and incidence of new use 
of prescription drugs for non-medical use reflects abuse of drugs depends on how 
“abuse” is defined.  If any use of a substance specifically for the feeling it causes and not 
for a prescribed indication is considered abuse, then the above statistics suggest an 
increase in abuse.  If a diagnosis of a substance abuse or dependence disorder is required, 
a different set of reports must be examined. 
The July 2004 Drug and Alcohol Services Information System (DASIS) report 
points out that between the years of 1992 and 2002, the rate of admission for treatment 
for the abuse of narcotic painkillers more than doubled (OAS 2004).  The total number of 
treatment admissions between 1997 and 2002 increased by 17%; however, the number of 
admissions for primary abuse of narcotic painkillers rose 186%, while treatment 
admissions for heroin abuse increased by 21% (OAS 2004).  This is strongly indicative of 
an increase in prescription drug abuse, specifically that of narcotic painkillers. 
Both the non-medical use of prescription drugs and treatment admission rates for 
prescription drug abuse have been on the rise, particularly in the last 5–10 years.  These 
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trends unmistakably convey that prescription drug abuse in the United States is a public 
health problem. 
Terminology of Substance Abuse and Dependence 
The definitions of addiction, abuse, and dependence have been debated by 
scientists and researchers for decades.  Numerous review and opinion papers propose 
definitions and appropriate use of the words.  In 2001, the American Academy of Pain 
Medicine, the American Pain Society, and the American Society of Addiction Medicine 
formed the Liaison Committee on Pain and Addiction (LCPA), and developed working 
definitions of “addiction, physical dependence, and tolerance” and recommended their 
use (Savage, Joranson, Covington, Schnoll, Heit, Gilson 2003).  Addiction was defined as 
“a primary, chronic, neurobiologic disease, with genetic, psychosocial, and 
environmental factors influencing its development and manifestations. It is characterized 
by behaviors that include one or more of the following: impaired control over drug use, 
compulsive use, continued use despite harm, and craving.” (Savage et al 2003).  Physical 
dependence was defined as “a state of adaptation that is manifested by a drug class 
specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose 
reduction, decreasing blood level of the drug, and/or administration of an 
antagonist.”(Savage et al 2003).  Tolerance was defined as “a state of adaptation in which 
exposure to a drug induces changes that result in a diminution of one or more of the 
drug's effects over time.” (Savage et al 2003).  The LCPA has not yet provided 
  
6
definitions for “psychic or psychological dependence,” and “abuse,” two other terms of 
interest in this study. 
Two NIDA websites refer to the Diagnostic and Statistical Manual of Mental 
Disorders, 3rd and 4th editions (DSM-III-R and DSM-IV) for criteria-based definitions of 
substance abuse and dependence and offer working definitions of “psychoactive 
substance use,” “psychoactive substance abuse (or problematic use),” and “addiction.” 
(available at http://165.112.78.61/Diagnosis-Treatment/Diagnosis2.html, 
http://www.nida.nih.gov/Drugpages/DSR.html).  One website indicates that “drugs may 
be used in a socially accepted or medically sanctioned manner to modify mood or state of 
mind.”  Having a drink with a friend or taking anxiolytic agents for anxiety as directed by 
a physician is classified as psychoactive substance use.  “Psychoactive substance abuse or 
problematic use” is defined as “the use of a substance…in a manner that is illegal or 
harmful to oneself.”  A distinct definition of “addiction” is not given, although the 
website describes it as being “characterized by the repeated, compulsive seeking or use of 
a substance despite adverse social, psychologic and/or physical consequences” (available 
at http://www.nida.nih.gov/Drugpages/DSR.html). 
Ferrell and colleagues performed a qualitative assessment of information in 
fourteen textbooks about opioid use and addiction potential.  They found that 
information, based on the researchers’ definition of “addiction,” was more often 
inaccurate than not, and highly varied in how “addiction” was defined and used (Ferrell, 
McCaffery, and Rhiner, 1992).   
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In a survey of 500 physicians, researchers gathered data about general knowledge 
of practitioners in the area of pain management, including the definition of “addiction” 
and legal issues associated with prescribing controlled substances.  Addiction was 
defined in a variety of ways by survey respondents, even when it was presented as a 
multiple choice question (Greenwald, Narcessian, and Pomeranz, 1999).   
The Federal Controlled Substances Act of 1970 also uses the word “addiction,” 
stating that an addict is one “who is so far addicted to the use of narcotic drugs as to have 
lost power of self-control with reference to his addiction” (available at 
http://www.usdoj.gov/dea/agency/csa.htm).  The Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition, text revision (DSM-IV-TR) does not use the word 
“addiction,” but instead gives criteria for “substance abuse” and “substance dependence,” 
respectively (American Psychiatric Association (APA), 2000).  Clearly, there is a lack of 
consensus of the definition and use of the language of substance abuse and dependence. 
Factors Affecting Physicians’ Prescribing Decisions 
A survey study by Potter et al in 2001 determined that a low level of concern 
about physical dependence, tolerance, and addiction was the most significant predictor of 
the willingness of a physician to prescribe opioids to patients with chronic non-malignant 
pain.  The year of graduation from medical school was found to be significant in two 
models at p-values of 0.0025 and 0.0048 (Potter, Schafer, Gonzalez-Mendez, Gjeltema, 
Lopez, Wu et al., 2001).  Specifically, more recent graduation from medical school 
increased willingness to prescribe under the conditions of the models. Additionally, 
  
8
concern about regulatory scrutiny was significant (p=0.0424), with fear of regulatory 
scrutiny limiting the willingness to prescribe opioids (Potter et al., 2001). 
In a 1994 study of physicians conducted by Turk and colleagues, 1912 of 6962 
physicians (response rate 27.46%) returned a questionnaire with items regarding years of 
practice, frequency of long-term treatment with opioids, number of chronic pain patients 
treated, and concerns about regulatory pressure, among other variables.  The purpose of 
this study was to assess the attitudes and practices of physicians with regard to long-term 
prescribing of opioids for non-cancer pain.  There was a significant difference found in 
the frequency of prescribing opioids long-term among the specialties (ANOVA p<0.001). 
Rheumatologists were significantly more likely to prescribe opioids long-term than any 
other specialty (p<0.003) (Turk, Brody, Okifuji, 1994).  This suggests that specialty is a 
predictor of physician prescribing decisions but provides no information on the 
significance or amount of the variance explained in physician prescribing decisions. 
Weinstein and colleagues from the University of Texas also conducted a survey 
about the use of opioid analgesics.  A 59-item questionnaire was employed to identify 
how physicians’ attitudes and knowledge contribute to pain management practices.  Four 
scales were identified: reluctance to prescribe opioids, fear of patient addiction, tolerance, 
or dependence, fear of regulatory agency scrutiny, and knowledge about pain and its 
treatment.  Correlating the fear of regulatory scrutiny scale with medical discipline 
revealed that internists had decreased fear compared to anesthesiologists/surgeons, but 
this difference was not statistically significant (Weinstein, Laux, Thornby, Lorimor, Hill, 
Thorpe, and Merrill, 2000). 
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Another survey examining prescription decisions used a series of 24 patient cases 
to measure physician prescribing of benzodiazepines while varying four factors.  These 
four factors were health status, psychiatric diagnosis, stability of job and marriage, and 
short-term ability to work.  Psychiatric diagnosis and the health status of an alcohol-
related medical problem were found to be significant predictors of agreement to prescribe 
benzodiazepines.  Added to the regression model were physician characteristics of year 
of graduation from medical school and specialty, among others.  This study did not find 
the physician characteristics to be significant with regard to physician prescribing 
decisions (Brown, Brown, Saunders, Castelaz, and Papasouliotis, 1997). 
A survey of emergency department physicians also used vignettes to identify 
factors influencing prescribing decisions.  One of the specific aims of this project was to 
“determine whether physicians’ characteristics are associated with either their baseline 
likelihood of opioid prescribing or their responses to additional information.”  Year of 
graduation from medical school and specialty were among the variables included in 
physician characteristics examined.  This study did not find any significance in any 
physician characteristics with regard to prescribing of opioid medications (Tamayo-
Sarver, Dawson, Hines, Cydulka, Wigdon, Albert, Ibrahim, Baker, 2004). 
 In summary, factors found to influence physician prescribing decisions 
include concern about dependence, length of physician practice, diagnosis, fear of 
regulatory scrutiny, and physician specialty.  Other factors found to affect physician 
prescribing decisions include: potency of drug prescribed, indication for which drug is 
prescribed, patient's history of drug abuse, familiarity with guidelines, medical discipline 
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or specialty, and age of physician (Schumock, Walton, Park, Nutescu, Blackburn, Finley, 
and Lewis, 2004; Davies and Huxley, 1997). 
Problem Statement 
The review of the literature surrounding substance abuse and dependence 
terminology prompted a preliminary exploration of package inserts, an important source 
of information for prescribers.  The use of terminology and amount of information in the 
sample of package inserts studied was found to be highly varied, with no predictable 
patterns across classes or controlled substance schedules (Phipps, Balster, Slattum, and 
Kirkwood, in press).  Education of health care providers using materials with non-
standardized terminology and varied information about substance abuse and addiction 
could lead to variability in physician understanding. This could affect decisions that 
physicians make about prescribing medications, which could affect the quality of 
substance abuse treatment and social aspects of substance abuse research.  
Significance 
This study aims to increase knowledge about how physicians interpret 
terminology associated with substance abuse and dependence information in package 
inserts and to characterize how this variability affects prescribing decisions made by 
physicians. The information generated in this study can be used as groundwork for 
additional studies in the communication of information to physicians and the 
development and evaluation of clearer, more useful package inserts. 
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Objectives 
Prescription drug abuse is an on-going problem in the United States.  Educating 
health care providers about substance abuse issues is an important factor in both the 
prevention and treatment of prescription drug abuse.  Package inserts are an important 
source of drug information for health care providers, and variability in substance abuse-
related terminology use in package inserts is high (Phipps et al, in press). Using survey 
research methods, this project aims to: 
1) Describe how physicians define the terms drug dependence and addiction 
2) Characterize sources used by physicians for drug abuse and dependence and other 
drug information  
3) Portray the scope of the problem of varied terminology in package inserts by 
characterizing its effects on physician prescribing decisions when modeled with 
covariates of physician and patient characteristics 
4) Provide groundwork for research designed to evaluate and develop more useful 
package inserts. 
Summary 
Review of literature has revealed a lack of consensus of the language surrounding 
the public health problem of substance abuse and dependence.  This project is intended to 
elucidate how this variability affects prescribing decisions made by physicians. 
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2 Literature Review 
CHAPTER 2 
Literature Review 
Overview 
This chapter offers a more in-depth review of the literature summarized in 
Chapter 1 and provides support for the variables included in the survey study. 
Prescription Drug Abuse in the United States 
The National Survey on Drug Use and Health (NSDUH), formerly known as the 
National Household Survey on Drug Abuse (NHSDA), is funded by the Substance Abuse 
and Mental Health Services Administration (SAMHSA).  SAMHSA is an agency under 
the United States Department of Health and Human Services (DHHS).  Periodically, 
SMHSA’s Office of Applied Studies (OAS) publishes its findings in a series of reports.  
These reports provide information about the prevalence and incidence of drug use in the 
United States.   
As stated in the Introduction, NSDUH reports have shown an increase in both 
incidence and prevalence of non-medical use of prescription drugs over the 11 years 
spanning 1990 and 2001.  The four classes of prescription drugs included in the NSDUH 
are pain relievers, stimulants, tranquilizers, and sedatives.  Non-medical use is defined as 
“use of prescription-type drugs not prescribed for the respondent by a physician or used 
only for the experience of feeling they caused.” 
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A sample of households in the U.S. is randomly selected, and each is personally 
visited by an interviewer, who obtains consent and administers the questionnaire.  Most 
of the questionnaire is self-administered on a computer, with a few questions asked and 
entered by the interviewer.   
It is important to note that several changes in methodology and analysis occurred 
in 2002, making it difficult to compare data collected before 2002 to data collected from 
2002 onward.  One of the changes in methodology that occurred in 2002 is the name 
change of the survey from National Household Survey on Drug Abuse to the National 
Survey on Drug Use and Health.  Because of the problem of social desirability in survey 
research, the current name could have had an impact on response rate, particularly those 
who do not use drugs recreationally, as they may be less likely to participate in a survey 
on “drug abuse” than on “drug use and health.”  A second change in methodology is the 
addition of a $30 incentive for participants, which could also affect response rate in the 
general population.  In fact, the response rate increased from ~73% in 2000 to ~78% in 
2002, and has remained at about 78% for 2003 and 2004 (NHSDA 2000 and NSDUH 
2004).  Other changes have included techniques employed for weighting the samples, 
wording and addition of questions, and format of the informational brochure given to 
respondents.  
Chapter 1 of this document illustrated the escalation in incidence of prescription 
drug categories from 1990 to 2001.  New non-medical use of pain relievers proved the 
largest increase, from 628,000 in 1990 to 2.4 million in 2001 (Office of Applied Studies 
(OAS), 2003).  For the same years, new users of stimulants rose from 270,000 to 808,000 
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and tranquilizer initiation soared from 373,000 to 1.1 million.  New use of sedatives, 
however, has remained under 300,000 new users since 1981.  Initiation of sedatives 
peaked at 638,000 in 1977, then steadily dropped off and remained fairly stable.  While 
the number of new users of sedatives has remained under 300,000, it has recently begun a 
slow but steady rise, from 111,000 in 1995 to 175,000 in 2000 (OAS, 2003).  Clearly, 
while sedatives have not proven to be as popular for new users, tranquilizers, stimulants, 
and especially prescription pain relievers have shown large increases in the estimated 
incidence of new use over the 11 years spanning 1990 to 2001.  It is interesting to note 
that there seems to be an actual decrease in new use of these three categories of drugs 
from 2000 to 2001.  Pain reliever initiation dropped from 2.7 to 2.4 million, tranquilizers 
from 1.3 to 1.1million, and stimulants from 983,000 to 808,000 (Office of Applied 
Studies, 2003).  Because of the aforementioned methodology changes of 2002, however, 
data collected beyond this point cannot be used to determine whether or not this is the 
beginning of a downward trend. 
In recent years, new use of prescription drugs for non-medical purposes seems to 
have stabilized.  From 2002 to 2004, first time non-medical use of pain relievers lingered 
at ~2.4 million, tranquilizers at ~1.2 million, stimulants steadied in the 700,000’s, and 
sedatives continue to remain under 300,000. (https://nsduhweb.rti.org/).  As stated 
previously, however, because of the methodology changes of 2002, data collected before 
2002 cannot be compared to data collected after 2002, making trend analysis for recent 
years unreliable.  Several more years of data are needed to determine whether any trend is 
present, with 2002 data serving as a new baseline. 
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In addition to incidence, or new use of prescription drugs, SAMHSA gathers 
information on lifetime prevalence and estimates past-year and past-month prevalence.  
From 2000 to 2001, lifetime non-medical use of prescription drugs significantly rose 
from 32.4 million to 36.0 million (p<0.01) (OAS, 2001).  Also significant at the p<0.01 
level are the increases in past-year prevalence, from 3.9% (8.76 million) to 4.9% (11.10 
million), and past-month prevalence, from 1.7% (3.85 million) to 2.1% (4.81 million) 
(OAS 2001).  Past-month prevalence is indicative of current use. 
From 2002 to 2004, overall lifetime non-medical use of psychotherapeutics has 
increased from 46.8 million to 48.0 million (http://oas.samhsa.gov/nhsda.htm).  Again, it 
is important to mention that a conclusion cannot be drawn about the apparent increase 
from 36.0 million in 2001 to 46.8 million in 2002.  Past-year prevalence has remained 
steady at about 14.6 million users, or about 6.2% of the population, as has past-month 
prevalence, at about 6 million or 2.5% of the population 
(http://oas.samhsa.gov/nhsda.htm).  
In 2002, the prevalence of non-medical pain reliever use in the U.S. was estimated 
at 13%, or almost 30 million people aged 12 or older (Office of Applied Studies, 2004).  
Males were more likely than females to have used a prescription pain reliever non-
medically (14.3 vs. 11.0%) in their lifetime, and Caucasians were more likely than other 
race/ethnicities (White: 13.6%, Black: 9.7%, Asian: 7.0%, Hispanic: 11.0%).   
It is interesting to note that with regard to specific substances, tramadol, a non-
controlled pain reliever available only by prescription, was used nonmedically by 
approximately 1 million people, which is similar to the estimated use of methadone (0.9 
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million) and Dilaudid® (1.1 million) (Office of Applied Studies, 2004).  OxyContin® 
and morphine users were at 1.9 and 2.1 million, respectively.  The most highly used pain 
relievers were found to be propoxyphene containing (Darvocet® and Darvon®), and 
Tylenol® with codeine, at 18.9 million, followed by hydrocodone products (Vicodin®, 
Lortab®, and Lorcet®) at 13.1 million (OAS, 2004).  Codeine products weighed in at 6.9 
million users.   
Looking at the data collected from 2002 to 2004, lifetime non-medical use of pain 
relievers has increased from 29.6 to 31.8 million users (p<0.05).  Again, propoxyphene 
containing products remained the most commonly used pain relievers at 9.0%, followed 
by hydrocodone and then oxycodone containing products at 7.9% and 4.9%, respectively.   
Tramadol containing products were estimated as being used by 0.5% of the population 
(http://oas.samhsa.gov/nhsda.htm).  
While in the youth age group (12 – 17 years), lifetime non-medical pain reliever 
use prevalence seems to have risen from 2001 to 2002 (9.6 to 11.2%) and non-medical 
stimulant use prevalence from 3.8 to 4.3%, it is difficult to interpret this phenomenon 
because of the previously mentioned changes in measurement methodology from 2001 to 
2002.  In recent years, however, the overall prevalence of lifetime non-medical use of 
pain relievers in youths aged 12-17 years has remained fairly constant, at 11.2% in 2002 
and 11.4% in 2004.  However, the non-medical use of Oxycontin® has increased in 
prevalence from 0.9 to 1.2% (p<0.05).  Lifetime use of stimulants has decreased in 
prevalence from 4.3% to 3.4% (p<0.01), and prevalence for tranquilizers and sedatives 
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has remained constant at about 3.3% and 1.0%, respectively 
(http://oas.samhsa.gov/nhsda.htm).  
Some may argue that illicit drugs like heroin pose a much larger problem than 
abuse of prescription drugs.  On January 21, 2005, SAMHSA released a new report based 
on data collected from the NSDUH in 2002 and 2003.  This report was comparing non-
medical use of oxycodone to heroin use.  From 2002 to 2003, the prevalence of lifetime 
non-medical use of oxycodone increased from 11.8 million to 13.7 million users, from 
5.0 to 5.8%.  Heroin use, however, remained steady at 1.6% prevalence of lifetime use 
(OAS 2005).  Therefore, not only is the prevalence for oxycodone higher than that of 
heroin to begin with, it is also increasing.  This might suggest that people are turning to 
prescription drugs as an alternative to illicit drug use, although further data are needed to 
determine whether or not this is an incidental phenomenon or a trend over time.  Further 
evidence supporting this theory was reported in a recent publication from NIDA, noting 
from the NSDUH 2003 survey that while the abuse of some drugs such as LSD and 
Ecstasy fell, the lifetime abuse of prescription medications, particularly narcotic 
painkillers, significantly increased from 2002 to 2003, with the young adult age group 
(18-25 years) showing a 15% increase in lifetime and past-month nonmedical use of pain 
relievers (NIDA 2004, OAS 2004). 
The Drug and Alcohol Services Information System (DASIS) report is a source of 
information on substance abuse treatment services.  Like the NSDUH report, it is 
published periodically by the Office of Applied Studies at SAMHSA. As mentioned in 
the introductory chapter, the July 23, 2004 report indicates that between the years of 1992 
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and 2002, the rate of admission for treatment for the abuse of narcotic painkillers has 
more than doubled (OAS 2004).  The total number of treatment admissions between 1997 
and 2002 increased by 17%; however, the number of admissions for primary abuse of 
narcotic painkillers rose 186%, while treatment admissions for heroin abuse increased by 
21% (OAS 2004).  This further underscores the problem associated with abuse of 
prescription drugs, particularly pain medications. 
This report also reports admission rates by state, as number of admissions per 
100,000, in categories of <14, 14-18, 19-23, or ≥24.  There is a trend upward in the 
number of states that have reached the category of ≥24/100,000.  Specifically, the number 
of states reporting admission rates of ≥24/100,000 has increased from 5 in 1992, to 11 in 
1997, to 31 states in 2002 (OAS 2004).  Notably, the highest rates were in Maine and 
Connecticut (207 and 89 per 100,000, respectively).  This perhaps suggests a need for a 
shift in the scale of how admission numbers are categorized.  A promising trend noted is 
that the median duration of use before first seeking treatment has decreased.  In 1992, 
people abused drugs for a median of 9 years before first seeking treatment, and this has 
decreased to 7 years in 1997, and further decreased to 4 years in 2002 (OAS 2004).  
While this indicates that people are getting treatment faster, this may also mean an 
increase in the need for resources for treating substance abusers of prescription drugs.  
Both the non-medical use of prescription drugs and treatment admission rates for 
prescription drug abuse have been on the rise, particularly in the last 5–10 years.  These 
trends clearly demonstrate that prescription drug abuse in the United States is a public 
health problem. 
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Terminology Variability 
As mentioned in the introductory chapter, there are currently many different 
views on the definition of “addiction.”  Numerous committees and organizations have 
proposed appropriate definitions and use for the term.  Some of these have included: the 
American Psychiatric Association, the National Institute on Drug Abuse, and the Liaison 
Committee on Pain and Addiction (LCPA) formed by the American Academy of Pain 
Medicine. 
LCPA defined addiction as “a primary, chronic, neurobiologic disease, with 
genetic, psychosocial, and environmental factors influencing its development and 
manifestations. It is characterized by behaviors that include one or more of the following: 
impaired control over drug use, compulsive use, continued use despite harm, and 
craving.”   
Two NIDA websites refer to the Diagnostic and Statistical Manual of Mental 
Disorders, 3rd and 4th editions (DSM-III-R and DSM-IV) for criteria-based definitions of 
substance abuse and dependence and offer working definitions of “psychoactive 
substance use,” “psychoactive substance abuse (or problematic use),” and “addiction” 
(http://165.112.78.61/Diagnosis-Treatment/Diagnosis2.html, 
http://www.nida.nih.gov/Drugpages/DSR.html).  One website indicates that “drugs may 
be used in a socially accepted or medically sanctioned manner to modify mood or state of 
mind.”  This is classified as psychoactive substance use, and gives the examples of 
having a drink with a friend and taking anxiolytic agents for anxiety as directed by a 
physician.  “Psychoactive substance abuse or problematic use” is defined as “the use of a 
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substance…in a manner that is illegal or harmful to oneself.”  A distinct definition 
“addiction” is not given, although the website describes it as being “characterized by the 
repeated, compulsive seeking or use of a substance despite adverse social, psychologic 
and/or physical consequences” (http://www.nida.nih.gov/Drugpages/DSR.html). 
The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text 
revision (DSM-IV-TR) does not use the word “addiction,” but instead gives criteria for 
“substance abuse” and “substance dependence,” respectively (American Psychiatric 
Association, 2000). 
While no studies specifically addressing substance abuse terminology in package 
inserts were found, textbook content has been previously examined.  A qualitative 
assessment of information about opioid use and addiction potential in fourteen textbooks 
was performed by Ferrell, McCaffery, and Rhiner (1992).  Of the fourteen texts 
examined, eight were pharmacology and six were medical/surgical textbooks.  
Information was assessed based on two questions: 
1) Is addiction defined as psychological dependence and distinguished from 
tolerance and physical dependence in accordance with current definitions used by 
the American Pain Society (APS) and the World Health Organization (WHO)? 
2) Is the incidence of addiction accurately stated? 
 
The researchers do not specifically state a definition of addiction that was used as 
criteria, but in the introduction, they state that addiction is “a psychological and 
behavioral syndrome characterized by overwhelming involvement with obtaining and 
using the drug for effects other than pain relief” (Ferrell, et al, 1992).  They assert that 
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only one of the fourteen textbooks used the correct definition of addiction, and that 
frequently, textbooks used the term “dependence” without specifying physical or 
psychological.  A few of the statements found in the textbooks evaluated are as follows 
(Ferrell, et al, 1992): 
• “Addiction and psychological dependence are defined as separate entities.” 
• “Addiction is a process of physiological dependence which is characterized by the 
two primary components of tolerance and withdrawal syndrome.” 
• “All narcotics created psychologic and physical dependence and tolerance…” 
 
A textbook outlining symptoms of morphine abuse included constipation and withdrawal 
symptoms on the list.  The same textbook that was deemed to have the correct definition 
of addiction was also the only one to also correctly state that the incidence of iatrogenic 
addiction to opioids when used for medical reasons is less than 1% (Ferrell, et al, 1992).  
While this study is highly subjective and detailed information about how the qualitative 
evaluation took place, the results of this study suggest that there is variability in the 
information used in the didactic training of students entering the health care profession.  
It did not address drug information resources used by current practitioners. 
It stands to reason, then that health care professionals exposed to the variety of 
sources available to them might differ in how they perceive the term “addiction.”  
Greenwald et al conducted a survey of 500 physiatrists in the United States, randomly 
selected from the list of members of the American Academy of Physical Medicine and 
Rehabilitation (AAPMR).  Each of the selected physicians received a cover letter, a 
questionnaire, and stamped return envelope.  Non-responders received a second packet 
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three weeks later.  A response rate of 50.6% complete enough for analysis was achieved 
(Greenwald, Narcessian, Pomeranz, 1999).  Questionnaire items addressed the types of 
patients treated, drugs the physicians were willing to prescribe for cancer and non-cancer 
pain, pharmacologic and legal aspects of opioid use, and the definition of “addiction.”  
Demographic information gathered included the physicians’ age, state, and the year of 
medical school completion. 
The definition of “addiction” was asked as a multiple choice question.  Physicians 
were asked to choose one or more of the following: physical dependence, tolerance, 
and/or psychological dependence.  An answer of “don’t know” was also an option.  Table 
2.1 shows the respondents’ answers. 
 
Table 2.1  Definitions of addiction* 
Terms chosen % respondents
Physical dependence, tolerance, 
and psychological dependence 27
Physical dependence and tolerance 2
Psychological dependence and tolerance 2
Physical and psychological dependence 26
Physical dependence 14
Psychological dependence 25
Don’t know 3
*Data compiled from Greenwald et al 1999 
 
This finding supports the idea that physicians have varying views on what addiction 
means. 
A true/false item on the questionnaire revealed that 14.4% of respondents either 
thought that a patient would become addicted to opioids if used daily for one month 
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regardless of diagnosis (8.1%), or did not know (6.3%).  This could reflect a 
misconception of the incidence of iatrogenic addiction to opioids used for legitimate 
medical purposes; however, it could also be that the respondents differed in their 
perceptions of “addiction.”  Based on the results shown in Table 2.1, only 25% of 
respondents defined “addiction” as “psychological dependence,” which is what the 
researchers considered a correct answer (Greenwald et al, 1999). 
 The sampling frame chosen in this study limits the generalizability of results to 
members of the AAPMR, and only about 50% of physiatrists in the U.S. are members 
(Greenwald et al, 1999).  It is possible that physiatrists in the U.S. who are not members 
of AAPMR would answer differently from the respondents.  Even within the AAPMR 
sample, there was a difference noted in that 8.4% of respondents belonged to the 
AAPMR Pain Special Interest Group, but only 4.3% of AAPMR members overall belong 
to this group (Greenwald et al, 1999).  Additionally, because this study focused on 
specialists in physical medicine and rehabilitation, no conclusions can be drawn about 
possible opinions of physicians in other specialties.   
Factors Affecting Physicians’ Prescribing Decisions 
Many studies have aimed at identifying factors that affect decisions that 
physicians make when prescribing medications.  Several of them will be discussed in this 
section. 
In a 1994 study of physicians conducted by Turk, Brody, and Okifuji, 1,912 of 
6,962 physicians (response rate 27.46%) returned a questionnaire with items regarding 
  
24
years of practice, frequency of long-term treatment with opioids, number of chronic pain 
patients treated, and concerns about regulatory pressure, among other variables (Turk, et 
al 1994).  The stated purpose of this study was to assess the attitudes and practices of 
physicians with regard to long-term prescribing of opioids for non-cancer pain (Turk, et 
al 1994).  Upon further examination of the methods and analysis, it appears that there was 
a particular interest in physician specialty and region of practice in the United States.  
Each of the aforementioned variables was analyzed by ANOVA against physician 
specialty and region of practice.  There were 5 regions of practice: Northeast, Midwest, 
Southeast, Southwest, and Pacific.  Four specialty areas were identified from seven 
originally chosen.  Those four were: general practice, surgery, rheumatology, and 
neurology/physiatry.  General practice was made up of family practice and internal 
medicine specialties, while surgery contained neurosurgeons and orthopedic surgeons.  
Additionally, neurologists and physiatrists were combined into a single group, called 
NPM.  The sample was a stratified, random sample of physicians in the United States.  A 
random sample of physicians from two states in each of the five regions was chosen to 
receive a questionnaire. 
Frequency of prescribing opioids was measured on a 7-point Likert scale where 0 
indicated “never” and 6 was defined as “very frequently.”  There was a significant 
difference found in the frequency of prescribing opioids long-term among the specialties 
(ANOVA p<0.001) (Turk, et al, 1994).  Not surprisingly, rheumatologists were found to 
prescribe long-term opioids more frequently than any other specialty (mean=1.98, 
SD=1.45), with surgeons reporting the least frequent prescribing of opioids for persistent 
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pain (mean=1.14, SD=1.31) (Turk, et al, 1994).  The use of parametric statistics for this 
analysis is questionable.  While the sample size was very large and a 7-point Likert scale 
is often treated as continuous data, the results for the surgery group, specifically a 
standard deviation greater than the mean, imply that a negative answer was possible, 
which it was not.  Therefore, these results must be interpreted with some caution.  It is 
unknown whether or not Kruskal-Wallis, the non-parametric analogue to ANOVA, would 
have shown statistical significance.  It is also interesting to note the wording of this item 
on the questionnaire: “How frequently do you prescribe chronic (maintenance) opioids 
for persistent pain?”  While the other items on the questionnaire specify and even stress 
non-cancer pain in italics, this item indicates only “persistent” pain and could have been 
interpreted differently by some physicians. 
Other items on the questionnaire addressed concerns about addiction, tolerance, 
and physical dependence.  Because these items were found to be significantly correlated 
(p<0.001), they were collapsed into a category designated as “concerns about ATD” 
(Turk, et al, 1994).  The mean score for the items was used as the ATD score.  ANOVA 
indicated that there was a significant difference in these scores among the specialties 
(p<0.001) (Turk, et al, 1994).  Again, the greatest difference was between 
rheumatologists and surgeons, showing the least concern and the greatest concern, 
respectively, although Tukey’s HSD test indicated that each group differed significantly 
from the others (Turk, et al, 1994). 
With respect to region of the country, frequency of prescribing differed 
significantly (p<0.001), but concerns about ATD did not (Turk, et al, 1994).  Physicians 
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in the Midwest were less likely to prescribe maintenance opioids for persistent pain than 
those in the Southeast or the West (Turk, et al, 1994).  Additionally, physicians in states 
where multiple prescriptions are required for CII medications demonstrated a 
significantly lower frequency of prescribing than those states not requiring multiple 
prescriptions (p<0.001) (Turk, et al, 1994).  However, these data must also be interpreted 
with caution, as there were only three out of the ten states chosen that required multiple 
prescriptions, indicating the likelihood that the sample sizes were not equal in the groups, 
as is assumed in ANOVA.  Furthermore, the degrees of freedom for the ANOVA were 
reported as 1 and 1,225 (Turk, et al, 1994).  With a returned sample size of 1,912, this is 
indicative of a large amount of missing data for this question. 
The results of this study suggest that practice specialty is a predictor of physician 
prescribing decisions but provides no information on the significance or amount of the 
variance explained in physician prescribing decisions. 
In 2001, Potter and colleagues conducted a survey of primary care physicians who 
were part of the University of California, San Francisco/Stanford Collaborative Research 
Network (CRN).  Any member of the network who was not involved with the study was 
chosen to receive a questionnaire, resulting in a sample size of 230 (Potter et al, 2001).  
Multiple contacts, including 2 mailed reminders and up to 3 phone calls, were used to 
increase response rate.  The questionnaire was made up of 3 patient case scenarios with 
follow-up questions, items related to attitudes about opioids and prescribing decisions, 
and demographics.  The purpose of the study was to gain insight into physicians’ 
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attitudes toward the use of opioids in chronic, non-malignant pain (CNMP) and factors 
affecting willingness to prescribe opioids. 
The dependent variable, willingness to prescribe opioids, was measured in three 
ways.  First, a sum scale was created from answers to the follow-up question from the 
vignettes: “If the pain persisted unchanged, would you prescribe opioids for this patient 
on a long-term basis?”  The second model was measured as level of agreement with a   
statement about prescribing CIII medications on an as-needed basis for CNMP, and the 
third model for CII medications on a scheduled basis for CNMP. 
Independent variables included patient variables, which were included in the 
vignettes, and physician demographics.  There were 2 significant predictors for the first 
model and three each for the second and third models.  Lower level of concern about 
physical dependence was a significant predictor of willingness to prescribe opioids in all 
three models, with R2 values of 0.21 (p=0.0001), 0.07 (p=0.0011), and 0.15 (p=0.0001), 
respectively (Potter et al, 2001).  Originally, the researchers had also inquired about level 
of concern about tolerance and addiction and found these to be highly correlated with 
each other and with level of concern about physical dependence.  Because of this, the 
variables for concern about tolerance and addiction were dropped.  Therefore, it is 
assumed that lower level of concern about physical dependence also indicates a lower 
level of concern about addiction. 
More recent graduation from medical school was significant in Models 1 and 2, 
with R2 values of 0.04 (p=0.0025) and 0.05 (p=0.0048), respectively (Potter et al, 2001).  
Concern about regulatory scrutiny was significant for the second model, explaining 2% 
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of the variance in willingness to prescribe medications not requiring triplicates on an as-
needed basis (p=0.0424) (Potter et al, 2001).  For the third model, the other two 
significant predictors were enjoyment in working with chronic pain patients and lower 
patient case load, with R2 values of 0.06 (p=0.0014) and 0.03 (p=0.0103), respectively 
(Potter et al, 2001). 
Additionally, 16% of the respondents indicated that they would never prescribe 
opioids to someone with a history of substance abuse, 42% would never prescribe opioids 
to someone currently abusing drugs (Potter et al, 2001).  This, coupled with the 
significant predictor of concern about physical dependence, suggests that a patient’s 
history of substance abuse would affect physician prescribing decisions. 
Only 2% indicated that they would never prescribe CIII medications on an as-
needed basis, but 35% said they would never prescribe CII medications on a scheduled 
basis for CNMP (Potter et al, 2001).  There also seemed to be differences in willingness 
to prescribe opioids based on diagnosis, but all of the diagnoses presented were CNMP, 
and no indication of statistical significance was noted in the article.  These findings 
suggest that the level of control of a substance and diagnosis also affect physician 
prescribing decisions. 
One limitation of this study is the extremely narrow sampling frame used.  While 
the researchers obtained a high response rate of 70% (Potter et al, 2001), only physicians 
in a small area were chosen to participate in the study, so the generalizability is limited to 
primary care physicians in the CRN.  This is very small number of primary care 
physicians, as indicated by the sample size of 230, which was the entire population of the 
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group except for those who were involved in the study itself.  Another limitation is found 
in the design of models 2 and 3.  Each model was based on the answer to a single 
question. Because the question varied on both the level of control of the substance and 
the dose scheduling, it is impossible to tease out the individual effects that either of these 
might have alone.  Because this study was designed to gather information on prescribing 
of opioids for CNMP, all of the diagnoses presented were types of CNMP.  Although 
statistical and practical significance of differences found in willingness to prescribe 
opioids for these conditions was not addressed, the differences were there.  If there are 
differences among diagnoses for the same type of pain, then it is certainly logical to 
assume that there would also be differences in prescribing decisions for different types of 
pain being treated.  
In the previously mentioned Greenwald survey study, researchers asked a series 
of questions about the legality and acceptability of prescribing opioids long-term for 
patients with cancer pain and chronic, non-malignant pain, with and without histories of 
opioid abuse.  For cancer pain, they found that the percentage of respondents finding 
long-term prescriptions for opioids both lawful and generally acceptable medical practice 
dropped from 95.4% to 73.8% if the patient had a history of opioid abuse.  Likewise, this 
percentage dropped from 36.9% to 10.5% for chronic, non-malignant pain without and 
with a history of opioid abuse, respectively.  This finding supports the hypothesis that a 
patient’s history of substance abuse could affect prescribing decisions, even for cancer 
pain. 
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Weinstein and colleagues also conducted survey about the use of opioid 
analgesics (Weinstein, Laux, Throndby, Lorimor, Hill, Thorpe, 2000).  A 59-item 
questionnaire was employed to identify how physicians’ attitudes and knowledge 
contribute to pain management practices.  Researchers aimed to explore how physician 
specialty and community size affected practices, and to identify barriers to effective pain 
management.  Medical disciplines identified were psychiatry, internal medicine, 
surgery/anesthesia, and other.  A random sample of physicians practicing in various 
regions of Texas was drawn from the Texas State Board of Medical Examiners’ database.  
The specific survey methods are not described in detail except to say that there were two 
mailings of the questionnaire.  Three hundred eighty-six physicians responded 
(Weinstein, et al, 2000).  The response rate, however, remains unknown, as the number of 
questionnaires mailed is not given. 
Factor analysis revealed three scales identifying barriers to adequate pain 
management: 
1) Reluctance to prescribe opioids (11 items), 
2) Fear of patient addiction, tolerance, or dependence (5 items), 
3) Fear of regulatory agency scrutiny (9 items). 
 
Other items measured knowledge about pain and its treatment (13 items), psychological 
attributes (18 items), and bias about sex and age (5 items).  The Likert scale used ranged 
from 1=Strongly agree to 7=Strongly disagree, so that a low sum score on a scale was 
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indicative of agreement.  For example, a low score on the reluctance scale would indicate 
that the physician has a high level of reluctance to prescribe opioids. 
With regard to physician specialty, no significant differences were found for the 
three barrier scales, although the authors state that results “approach significance” 
(Weinstein, et al, 2000).  According to the article, the trend is that psychiatrists appear to 
have lower reluctance and lower fear of patient addiction than the other specialties, and 
internists tend to have more fear of regulatory scrutiny while surgeons have less.  
Statistical significance (p<0.05) was achieved on items relating to psychological 
attributes; the article states that psychiatrists have a more open attitude than other 
specialties. (Weinstein et al, 2000). 
However, when looking at the mean scores, it appears that the results are opposite 
of the conclusions drawn in the article.  For example, the mean score on scale 1 for 
psychiatrists was 2.81, while the mean score for surgeons was 3.20.  Because the scale 
was defined as 1=Strongly agree and 7=Strongly disagree, this would imply that a lower 
score indicates agreement with the items.  Examining the items on scale 1, only one of 
them would be reverse-scored.  This item was worded “It is appropriate to escalate a dose 
of narcotics above the usual range if the prognosis is less than 1 year” (Weinstein, et al, 
2000).  Agreement with other items on this scale appears to indicate higher reluctance.  
For example, an item is phrased “Narcotics should be restricted to treatment of severe 
intractable pain” (Weinstein, et al, 2000).  Another item is worded “Persons who fit the 
‘profile’ of a likely drug abuser should never be treated with narcotics” (Weinstein, et al, 
2000).  Based on the scale defined by the researchers, agreement with these items would 
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result in a low score, not a high one.  Careful examination of the items on the other scales 
implies the same.  The specific interpretations of results in this article, then, are in 
question.  However, it can be said that in some cases, medical discipline matters, while in 
others, it does not. 
A survey examining benzodiazepine prescribing decisions was conducted by 
Brown and colleagues to assess the effect of clinical cues on decision making.  Also 
included in the analysis were physician variables such as year of medical school 
graduation, specialty, clinical interest, and other demographic information.  The sample 
of 226 was drawn from the staff directory at a Midwestern U.S. medical school.  
Recruitment into participation included two written invitations to schedule interviews, 
and a written version of the questionnaire sent to non-responders.  One hundred and three 
physicians in various specialties completed the survey via interview, and 13 filled out the 
written version.  Those who answered the written version did not differ in responses from 
those who completed interviews (Brown, et al, 1997).  Medical disciplines represented in 
this study included: allergy, cardiology, endocrinology, family practice, gastroenterology, 
general internal medicine, hematology, infectious disease, nephrology, neurology, 
oncology, psychiatry, pulmonology, rehabilitation, and rheumatology.  The highest 
number of respondents were in family practice (20 respondents), psychiatry (15 
respondents), and general internal medicine (13 respondents) (Brown, et al, 1997).  
Eleven oncologists participated, and the rest of the specialties had 9 or fewer respondents 
each (Brown, et al, 1997). 
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A series of 24 patient cases was used to measure physician prescribing of 
benzodiazepines while varying four factors: health status, psychiatric diagnosis, stability 
of job and marriage, and short-term ability to work.  Additionally, cues such as elevated 
liver function tests, unstable blood pressure, and esophageal reflux, which along with 
complaints of nervousness and insomnia can be suggestive of alcohol abuse, were varied 
in the scenarios.  Physician prescribing decisions were measured as level of agreement 
with continued prescribing of a patient’s current therapy, using a scale of –5 (strong 
disagreement) to +5 (strong agreement), with 0 eliminated in order to force a choice. 
The dependent variable was agreement with continued prescribing.  Variables of 
diagnosis and presence of alcohol-related medical problems were found to be significant 
at the 0.05 level (Brown, et al, 1997).  Long-term social stability, recent function, and 
interaction terms for alcohol-related medical problems with diagnosis were not 
significant (Brown, et al, 1997).  Also in the initial regression model were physician 
characteristics of year of graduation from medical school and specialty, among others.  
This study did not find these to be significant with regard to physician prescribing 
decisions (Brown et al, 1997). 
Many medical disciplines were included in this study.  However, the patient case 
scenarios were all about patients presenting specifically with psychiatric complaints.  
While it is logical to include general practitioners and psychiatrists in this sample, it is 
unlikely that some of the other specialties, such as allergy/immunology, would be making 
decisions about prescribing benzodiazepines for these patients.  It is unknown whether a 
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larger sample size with a more focused choice of medical disciplines included might 
yield different results. 
A survey of emergency department physicians also used vignettes to identify 
factors influencing physicians’ decisions to prescribe opioids (Tamayo-Sarver, Dawson, 
Hines, Cydulka, Wigton, Albert, et al., 2003).  The purpose of this study was to 
determine the effect of patient characteristics and diagnosis on physicians’ decisions to 
prescribe opioids for patients.  This was a large survey of 5,750 emergency physicians 
systematically (every second name) selected from the American College of Emergency 
Physicians (ACEP) membership list.  The survey packet in this study included a cover 
letter, the questionnaire, and a $2 bill for incentive (Tamayo-Sarver, et al, 2003).  Non-
responders were sent a reminder postcard, and then a second questionnaire.  The 
researchers achieved a response rate of 53% (Tamayo-Sarver, et al, 2003).  
Questionnaires were considered complete enough for analysis if one of the three vignettes 
was answered.  Three models were constructed, one for each of three diagnoses: ankle 
fracture, migraine, and back pain. 
Results showed that the patient characteristic of race/ethnicity was not significant 
for any of the models; p-values for migraine, back pain, and ankle fracture were 0.65, 
0.79, and 0.25, respectively (Tamayo-Sarver, et al, 2003). 
In summary, there have been several studies examining factors that affect 
physicians’ prescribing decisions under various conditions.  These studies have suggested 
that level of control of the medication, patient’s diagnosis, and patient’s history of 
substance abuse may play a role in physicians’ decisions to prescribe controlled 
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substances.  Physician specialty and length of practice may or may not be important, and 
patient race/ethnicity may not be important.  In this study, all of these variables will be 
put into the initial model except for patient race/ethnicity, which will be held constant. 
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3 Preliminary Study 
CHAPTER 3 
Preliminary Study 
Note:  This article will be forthcoming in the Journal of Addictive Diseases. 
Overview 
This chapter explains a preliminary study of package insert information on drug 
abuse and dependence.  At the time this dissertation was being written, the study had 
been accepted for publication in the Journal of Addictive Diseases. 
Background and Significance 
Among the responsibilities of the United States Food and Drug Administration 
(FDA) is that of ensuring the safety and efficacy of drugs that have a legitimate medical 
use.  Prescriber education is an integral part of facilitating the safe and proper use of 
medications.  The mechanism by which the FDA initially communicates information to 
health care providers is the FDA-approved product labeling, also called the package 
insert.  The package insert provides information on the risks and benefits of using a 
particular substance, the approved indications, dosing, pharmacokinetics, side effects, 
pharmacology, contraindications, warnings, and precautions.  Abuse and dependence 
potential of a drug is also included in this information.  Prescription drug abuse is an on-
going problem in the United States (Jongston, O’Malley, Bachman, Shulenbert, 2004; 
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Mohler-Kuo, Lee, Wechsler, 2001).  Because the FDA’s initial communication of drug 
information to prescribers is through the package insert, it is imperative that the drug 
abuse and dependence information contained in these package inserts use clear and 
consistent language in order to be clinically useful. 
Scientists have long debated the definitions of addiction, abuse, and dependence.  
Numerous review and opinion papers propose definitions and appropriate use of the 
words, and committees have been formed in an effort to standardize terminology (Dodes, 
1996; Maddux and Desmond, 2000; Peele, 1977; Goodman, 1990; Savage, Joranson, 
Covington, Schnoll, Heit, Gilson, 2003; Trachtenberg).  Use of these terms, however, 
continues to be an issue.  A qualitative assessment of information about opioid use and 
addiction potential in fourteen textbooks was performed by Ferrell et al.  They found that 
information, based on the researchers’ definition of “addiction,” was more often 
inaccurate than not, and highly varied in how “addiction” was defined and used (Ferrell, 
McCaffery, Rhiner, 1992). 
Considering the history of inconsistent use of terminology related to substance 
abuse and dependence, variability could be carried over into physician opinions. In a 
survey of 500 physicians, researchers gathered data about general knowledge of 
practitioners in the area of pain management, including the definition of “addiction” and 
legal issues associated with prescribing controlled substances.  Survey respondents 
defined addiction in a variety of ways even when it was presented as a multiple choice 
question (Greenwald, Narcessian, Pomeranz, 1999). 
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The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text 
revision (DSM-IV-TR) does not use the word “addiction,” but instead gives criteria for 
“substance abuse” and “substance dependence,” respectively (American Psychiatric 
Association, 2000).  Both are described as maladaptive patterns of substance use, the 
symptoms of which differ slightly in intensity and nature. 
The discrepancies in definitions for addiction, dependence, and abuse and usage 
among textbooks and the primary literature could potentially carry over into product 
labeling (package inserts).  This can lead to differences of opinion among prescribing 
physicians about a drug’s potential for abuse or dependence and influence prescribing 
decisions.  Other health care professionals (e.g., pharmacists, nurse practitioners) also 
interpret package insert information. Variability in definitions and usage can affect both 
prescribing and patient counseling information. 
No published systematic evaluations of abuse and dependence potential 
information in package inserts were found in a Medline search.  There have been studies 
of other categories of information in product labeling (e.g., pregnancy, hepatotoxicity) all 
of which revealed deficiencies in the information in question (Uhl, 2002; Spyker, Harvey, 
Harvey, Abernathy, 2000; Hung, Ponto, Gadient, 2004; Willy, Li, 2004; Mullen, 
Anderson, Kim, Blanc, Olson, 1997).  One such study reported that only 11% of a sample 
of over 100 pregnancy category X drugs contained, beyond a box warning or 
contraindication for use in pregnancy, specific risk management strategies such as 
obtaining negative pregnancy tests before initiation and during drug therapy (Uhl 2002). 
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A study by Spyker et al. assessed clinical pharmacology information in 76 
package inserts from the 1996 edition of the Physicians’ Desk Reference (PDR).  
Researchers in this study created a scale for the evaluation of the information and 
assigned each package insert a percentage score for containing predetermined 
information, such as identification of the active agent, its mechanism of action, and 
duration of effect.  The authors reported a median percentage score of 31% and 
concluded that package inserts are deficient in clinical pharmacology information 
(Spyker et al., 2000). 
Hung et al. identified five categories of problematic instructions in the package 
insert information for the preparation of radiopharmaceuticals: absent or incomplete, 
restrictive, inconsistent, impractical, and vague directions.  These researchers concluded 
that the information provided in FDA-approved product labeling should be considered 
guidance and not a requirement, and that nuclear pharmacists and physicians should be 
able to deviate from the methods provided in the package insert (Hung, et al, 2004). 
 Another study of FDA-approved product labeling examined the consistency and 
quality of information about hepatotoxicity for 95 prescription drugs from the 2000 PDR 
with a checklist used to create an informativeness score.  The mean informativeness score 
was 35% and the authors concluded that information provided in labeling is variable but 
may be improved by increasing consistency of information on hepatotoxicity in the 
product labels (Willy, Li, 2004). 
A comparison of overdose management information found in the PDR to 
toxicology references indicated that there are deficiencies in PDR overdose treatment 
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strategies.  The authors report that almost half of the evaluated PDR entries 
recommended either ineffective or contraindicated therapies (Mullen et al., 1997).  This 
study draws attention to the possibility of clinically inaccurate information in package 
inserts. 
Objective and Hypotheses 
Based on the historical lack of consensus on the use of drug abuse and 
dependence-related terminology and the inadequacy of package insert content suggested 
by prior reviews thereof, an evaluation of the drug abuse and dependence information in 
package inserts was conducted.  The purpose of this project was to describe and evaluate 
package insert content with regard to abuse and dependence potential for drugs that are 
dispensed in community pharmacies.  Package inserts for products in higher controlled 
substance schedules (those with lower schedule numbers which have higher abuse 
potential) should have stronger warnings and more information about drug abuse and 
dependence than those products with less abuse potential. 
Methods 
The American Hospital Formulary System (AHFS) 2003 was used to identify 
drugs that act in the central nervous system (CNS).  The following CNS-active drug 
classes were selected: 
• Analgesics and anti-pyretics: opiate agonists and partial agonists 
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• Anticonvulsants: barbiturates and benzodiazepines 
• Anorexigenic agents, respiratory stimulants, and cerebral stimulants 
• Anxiolytics, sedatives, and hypnotics: barbiturates, benzodiazepines 
• Miscellaneous central nervous system agents 
 
Drugs in these classes were then cross-referenced with the 2003 Electronic 
Physicians’ Desk Reference (E-PDR) (AHFS, 2003, Medical Economics Company, 
2003).  Drugs with brand names and full package inserts were included in the study.  
Generic products and injectable preparations were excluded.  A full list of package inserts 
included in the study is included as Appendix A of this document. 
Microsoft AccessTM was used to create a database.  The drug’s generic and brand 
name, manufacturer, Federal Controlled Substance Act (CSA) schedule, and AHFS 
therapeutic classification were recorded.  Package inserts in the E-PDR were reviewed by 
one researcher (LBP).  Information pertaining to drug abuse and dependence was then 
extracted into the database.   
In the first part of the study, each package insert was evaluated for content.  The 
main parameter assessed was the presence or absence of primary terms:  addiction, 
dependence, physical dependence, and psychological or psychic dependence.  Also noted 
was the presence or absence of other terms: habituation or habit-forming, tolerance, 
withdrawal, abstinence syndrome, drug-seeking behavior, misuse, abuse, diversion, 
craving, and illegal or illicit use. 
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A coding system was then created to further describe how the above terminology 
was used in the package insert.  For example, it was noted whether or not the term was 
described or defined in the package insert.  The strength of the warning about abuse 
potential was subjectively assessed for each package insert.  If the phrase “may cause 
dependence” was used, the warning was considered mild.  Statements that the drug “has 
been abused” or “has caused dependence” indicated a moderate warning.  Strong 
warnings about abuse potential were marked by phrases such as “actively sought out by 
drug abusers, diversion not limited to those with a history of substance abuse”, and the 
words “severe” or “extensive” being used to describe dependence on the drug.    Other 
codes included: the presence or absence of terminology indicating either evidence of no 
abuse or dependence potential or lack of information about abuse or dependence 
potential, the presence or absence of warnings regarding tapering of doses or 
consequences of abruptly stopping medication, and the presence of an entire section 
designated for abuse and dependence information.  A complete list of codes and their 
meanings is available as Appendix B of this document.  The number of sentences 
dedicated to information about abuse and dependence potential was recorded as a method 
of quantifying the amount of information in the package insert related to drug abuse or 
dependence.   
Descriptive statistics were used to characterize the data.  Frequencies were 
reported for parameters recorded as present or absent.  Central tendency and spread of the 
amount of information relating to drug abuse and dependence was quantified by median 
and range for number of sentences since the data were not normally distributed. Kruskall-
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Wallis was used to compare the amount of information across schedules for controlled 
substances (CII-V) and across warning strength categories.  Spearman’s Rho correlation 
was used to determine strength and significance of time trends in the amount of 
information using the original drug approval date and the date of the last label revision 
because the data for these continuous variables were not normally distributed. 
Results 
Of the 77 entries in the package insert database, 40 were opiate agonists, 18 were 
stimulants, and the remainder fell into one of the following categories:  opiate partial 
agonists, anticonvulsants, anxiolytic/sedative/hypnotics, or miscellaneous CNS agents.  
Twenty-nine records were in schedule II, 24 in schedule III, 15 in schedule IV, 1 in 
schedule V, and 8 were non-scheduled.  Table 3.1 shows the number of package inserts in 
each AHFS class and each Federal Controlled Substance Act schedule (CSA schedule). 
Table 3.1  Frequency of package inserts included in study of drug abuse and dependence warnings as 
a function of AHFS classes and CSA schedules 
AHFS Class / Federal Controlled Substance Act 
Schedule 
CII CIII CIV CV NS Total 
Analgesics:  Opiate Agonists 18 18 1 1 2 40 
Analgesics:  Opiate Partial Agonists 0 0 3 0 0 3 
Anticonvulsants:  Barbiturates 0 0 0 0 1 1 
Anticonvulsants:  Benzodiazepines 0 0 1 0 0 1 
Anorexigenics, Respiratory & Cerebral Stimulants 11 2 4 0 1 18 
Anxiolytics, Sedatives, Hypnotics: Barbiturates 0 3 0 0 1 4 
Anxiolytics, Sedatives, Hypnotics: Benzodiazepines 0 0 4 0 0 4 
Anxiolytics, Sedatives, Hypnotics: Miscellaneous 0 0 2 0 3 5 
Miscellaneous CNS agents 0 1 0 0 0 1 
Total  29 24 15 1 8 77 
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Of the eight non-scheduled products, two were opiate agonists (tramadol), five 
were anxiolytic/sedative/hypnotics (phenobarbital [2], hydroxyzine [2], promethazine 
[1]), and one was a stimulant (caffeine).    
Table 3.2 shows the frequencies of a section designated specifically for 
information about drug abuse and dependence for each AHFS class and CSA schedule.   
 
Table 3.2  Frequencies of sections specifically dedicated to information about drug abuse and 
dependence for each AHFS class and CSA schedule 
Class # Inserts Percentage 
Opiate Agonists 37/40 92.5 
Opiate Partial Agonists 3/3 100 
Anticovulsants: Barbiturates 0/1 0 
Anticonvulsants: Benzodiazepines 1/1 100 
Stimulants 14/18 77.8 
Anxiolytic, Sedative, Hypnotics: Barbiturates ¾ 75 
Anxiolytic, Sedative, Hypnotics: Benzodiazepines ¾ 75 
Anxiolytic, Sedative, Hypnotics: Miscellaneous 2/5 40 
Miscellaneous CNS agents 1/1 100 
Total 64/77 83.1 
Schedule   
CII 25/29 86.2 
CIII 24/24 100 
CIV 12/15 80 
CV 1/1 100 
Non-scheduled 2/8 25 
Total 64/77 83.1 
 
 
About 83% of the 77 package inserts had a section dedicated specifically to drug 
abuse and dependence information. Most opiate agonists and stimulants had a dedicated 
section for drug abuse and dependence information.  There was a dedicated section for 
  
45
drug abuse and dependence information in 100% of the inserts in CSA schedules III and 
V, although there was only one schedule V insert. 
Table 3.3shows the frequencies of package inserts in each AHFS class and CSA 
Schedule containing primary terminology.   
 
Table 3.3  Appearance of primary abuse and dependence-related terminology in package inserts 
from AHFS classes and CSA schedules 
Class Addiction Dependence Physical 
Dependence 
Psychological 
Dependence 
Abuse 
 
Opiate Agonists 13 25 39 36 29 
Opiate Partial 
Agonists 
0 2 3 2 3 
Anticovulsants: 
Barbiturates 
0 0 0 0 0 
Anticonvulsants: 
Benzodiazepines 
1 1 0 0 0 
Stimulants 1 14 2 16 17 
Anxiolytic, Sedative, 
Hypnotics: 
Barbiturates 
2 1 3 3 3 
Anxiolytic, Sedative, 
Hypnotics: 
Benzodiazepines 
1 4 4 4 1 
Anxiolytic, Sedative, 
Hypnotics: 
Miscellaneous 
2 2 1 0 2 
Miscellaneous CNS 
agents 
0 1 0 0 1 
Total: 20 50 52 61 56 
Schedule      
CII 11 24 18 26 27 
CIII 4 13 21 22 15 
CIV 5 11 10 10 11 
CV 0 1 1 1 1 
NS 0 1 2 2 2 
Total 20 50 52 61 56 
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The word “addiction” appeared in 26% of the 77 records (13/20 were opiate 
agonists).  The word “dependence” without distinction for physical or psychological was 
found in 65% of the 77 records (25/50 were opiate agonists, 14/50 were stimulants).  Of 
the primary terms, “psychological dependence” appeared most frequently (61/77 inserts). 
However, terms frequently associated with the concept of psychological dependence, 
such as craving and drug-seeking behavior, appeared only rarely (3 and 7 inserts, 
respectively).  The frequencies for presence of other terms are found in Table 3.4.  The 
two most commonly used of the other terminology were “tolerance” and “withdrawal.” 
 
Table 3.4  Appearance of other abuse and dependence-related terminology in package inserts 
Term Number of Package 
Inserts (n=77) 
Percentage 
(%) 
Tolerance 60 77.9 
Craving 3 3.9 
Withdrawal 53 68.8 
Abstinence Syndrome 14 18.2 
Misuse 16 20.8 
Diversion 4 5.2 
Habit-forming/Habituation 25 32.5 
Illicit/Illegal Use 2 2.6 
Drug-seeking Behavior 7 9.1 
 
Warning strengths are summarized for each AHFS class and CSA Schedule in 
Table 3.5. 
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Table 3.5  Strength of warnings about drug abuse and dependence appearing in each AHFS class and 
CSA schedule 
Class Strong Moderate Mild Total 
Opiate Agonists 3 10 27 40 
Opiate Partial Agonists 1 2 0 3 
Anticovulsants: Barbiturates 0 0 1 1 
Anticonvulsants: Benzodiazepines 0 0 1 1 
Stimulants 7 9 1 17* 
Anxiolytic, Sedative, Hypnotics: Barbiturates 0 3 1 4 
Anxiolytic, Sedative, Hypnotics: Benzodiazepines 0 2 2 4 
Anxiolytic, Sedative, Hypnotics: Miscellaneous 0 0 2 2* 
Miscellaneous CNS agents 1 0 0 1 
Total 12 27 34 73* 
Schedule     
CII 6 12 11 29 
CIII 2 7 15 24 
CIV 2 7 6 15 
CV 0 1 0 1 
Non-scheduled 2 0 2 4* 
Total 12 27 34 73* 
*The package inserts that had no warning about drug abuse were all non-scheduled; one for caffeine, 1 for 
promethazine, and 2 for hydroxyzine. 
 
Of those inserts with mild warnings, 88.2% were opiate agonists.  Of those with 
strong warnings, 58.3% were stimulants, 33.3% were opiate agonists (2/4 were non-
scheduled), and 8.3% (1 insert) was an opiate partial agonist. The strongest warnings 
appeared in cerebral stimulants and opiate agonists; however, the strength of warnings 
within AHFS classes was variable, particularly for the opiate agonists.  Many of the 
schedule II opiate agonists had mild warnings while two of the four opiate agonist/partial 
agonist products with strong warnings were non-scheduled (both contain tramadol). 
Strength of warning was not significantly different across CSA schedules (p=0.069), nor 
did it have any correlation with original approval date (p=0.610). 
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Eighteen (23.4%) package inserts indicated that abuse, dependence, or addiction 
was rare.  All but one of these 18 were opiate agonists. Thirteen said that “dependence” 
was rare, and 5 stated that “addiction” was rare.  The two that asserted “abuse” was rare 
also stated that “dependence” was rare. 
A boxed warning about drug abuse and dependence appeared in 51.7% of the 
schedule II drug records.  The percentage of records with boxed warnings in the 
remaining schedules was less than 15% each. 
The overall median number of sentences on drug abuse and dependence was 17 
with a range of 0-66.  The greatest variability was found among the opiate agonists 
(median 20, range 7-66 sentences).  There was high variability in all schedules except 
schedule V, in which there was only one entry (14 sentences).  Table 3.6 shows the 
median and range of sentences found in each CSA Schedule. 
 
Table 3.6  Number of sentences about drug abuse and dependence in each CSA schedule 
Schedule/Number of Sentences Number of Sentences: Median (Range) 
CII 15 (5-66) 
CIII 19 (9-48) 
CIV 15 (7-62) 
CV 14 (only one package insert was a CV) 
Non-scheduled 1 (0-28) 
 
 
The amount of information in controlled substances (scheduled II-V) did not 
significantly vary across CSA schedule (p=0.443), nor was it significantly different 
across warning strength categories (p=0.821).  There was a positive significant 
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correlation between the number of sentences and the original drug approval date 
(Spearman’s rho=0.429, p<0.001).  On the other hand, the correlation between the 
number of sentences and year of most recent label revision was not significant 
(Spearman’s rho= -0.040, p=0.749). 
Discussion 
Variability in information about drug abuse and dependence potential is high and 
can be confusing for health care professionals. Neither the strength of warning nor the 
amount of information dedicated to drug abuse and dependence significantly differed 
across CSA schedules, indicating that neither the amount of information on drug abuse 
and dependence nor the strength of the warning accurately reflects the CSA schedule into 
which a drug falls. For example, two inserts with strong warnings and a moderate amount 
of information (21 and 28 sentences, respectively) were non-scheduled. The warnings 
and amount of information in these cases seem to contradict the implication that the drug 
has little to no abuse liability based on its non-scheduled status. An explanation for the 
lack of relationship between warning strength and schedule control would be an overall 
increase in warning strength over time; however, original approval date did not correlate 
with warning strength. 
The sample of inserts in this study is heavily weighted toward opiate agonists, 
with stimulants being the second largest group.  While most package inserts explain or 
describe physical dependence, tolerance, and withdrawal, there is a lack of information 
about psychological dependence, which was the most frequently appearing of the primary 
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terms.  The word “addiction,” which is not universally defined and does not appear in the 
DSM-IV-TR, is frequently used.  Many words commonly associated with the idea of 
psychological dependence and addiction, however, are rare. 
The stimulants had stronger warnings and more boxed warnings about drug abuse 
and dependence than did opiate agonists.  Not surprisingly, however, the opiate agonists 
had more information about physical dependence, tolerance, and withdrawal; however, 
twelve opiate agonist package inserts indicated that “dependence” was rare. 
The amount of information, quantified by the number of sentences, is also highly 
varied, even within package inserts for the same drug.  For example, there were six 
entries for products containing oxycodone, and the number of sentences about drug abuse 
and dependence ranged from 7-66.  For morphine, six entries ranged from 9-46 
sentences.  
The amount of information on drug abuse and dependence increased over time 
with respect to the original approval date of the drug, but not the date of the latest label 
revision.  It is possible that the overall length of package inserts has also increased over 
time as approval requirements for detailed information also increase.  Thus, it is possible 
that the proportion of total package insert information related to drug abuse and 
dependence information has not changed; however, this remains unknown as the overall 
length of the package inserts was not collected in this study.  
There are several limitations to this study.  The E-PDR was the only source of 
package inserts used and only brand named drugs were included. Because manufacturers 
pay to have information published in the PDR, the content changes from year to year. 
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Consequently, a sample using the same selection criteria with a PDR from another year 
could yield a different number of package inserts and distribution of schedules and 
classes.  Likewise, the package inserts themselves may have been revised and differ from 
those collected in this data set in 2003. As a result, the sample of package inserts included 
in this study may not be representative of all of the drugs currently on the market. 
Although objective criteria were applied in the determination of warning strength, it was 
highly subjective, and only one person evaluated the package inserts.  Finally, the sample 
of package inserts used here was heavily weighted towards opiate agonists, with very few 
drugs in some of the other AHFS classes.  This makes it difficult to draw generalized 
conclusions about those classes with very few package inserts.  The same holds true for 
CSA Schedules; well over half of the package inserts were in schedules II and III, making 
it difficult to draw conclusions about variability within the other schedules.   
Conclusion 
Evaluation of 77 package inserts for CNS-active drugs demonstrated high 
variability in terminology related to drug abuse and dependence.  The confusion 
generated by this inconsistency can affect prescribing decisions of currently practicing 
physicians, patient counseling by pharmacists and other health care professionals, and the 
education materials that students in the health care arena receive. Consequently, the 
ambiguity and complexity of understanding drug abuse and dependence and its treatment 
is perpetuated. 
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The inconsistency found in this study indicates that package inserts are not a 
clinically useful source of information about abuse and dependence liability of 
prescription drugs in the U.S.  It then becomes important to determine if this variability 
also appears in health care provider’s opinions about the utility of information provided 
in package inserts, and to discover what sources of information are used to gain 
knowledge about abuse and dependence potential of prescription drugs. If, for example, 
the CSA schedule itself is significantly important to health care providers, this places 
great importance on the application of scientific information available when assigning 
schedule control during the approval process (Balster and Bigelow, 2003).  Until 
standardized, common language is in place, this variability will continue and perpetuate 
confusion about drug abuse and dependence. It is imperative to develop common 
language for use in package inserts to improve communication about abuse and 
dependence potential of prescription drugs and further attempt to prevent prescription 
drug abuse. 
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4 Methods 
CHAPTER 4 
Methods 
Overview 
This chapter describes the methods used to meet the objectives stated in Chapter 
1.  After the objectives are restated and briefly addressed, details of the sampling frame 
and scope of the project, the development and piloting of the questionnaire, the survey 
process, and data analysis are presented. 
Summary of Objectives 
Objective 1: Describe how physicians define the terms drug dependence and addiction. 
Physicians were asked to choose factors they felt were necessary for the 
clinical states of drug dependence and addiction to exist.  Frequencies were 
reported for descriptive purposes. 
Objective 2: Characterize sources used by physicians for drug abuse and dependence 
and other drug information.   
Physicians were asked to indicate how frequently they used various 
sources for drug abuse and dependence information and other drug information.  
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Mean values for these were calculated for the purpose of more accurately ranking 
the sources physicians consult. 
Objective 3: Portray the scope of the problem of varied terminology in package inserts 
by characterizing its effects on physician prescribing decisions when modeled 
with covariates of physician and patient characteristics. 
Physicians were presented with a series of four case scenarios with 
package insert excerpts representing a medication given to the patient.  Physician 
prescribing decisions were measured as comfort level with a prior physician’s 
choice, likelihood of refilling the prescription, and likelihood of choosing the drug 
if the respondent was the first physician to see the patient.  Additionally, 
physicians rated how useful they find a particular package insert excerpt to be in 
making a clinical decision. 
For physician, patient, and package insert characteristics, regression 
models tested whether coefficients were equal to zero.  Interactions for the 
variables history of substance abuse with type of pain and strength of warning 
were tested for coefficients of zero as well. 
Objective 4: Provide groundwork for research designed to evaluate and develop more 
useful package inserts. 
Areas for future research are discussed in Chapter 6. 
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Sampling Frame and Scope 
The sampling frame consisted of physicians currently licensed and residing in the 
Commonwealth of Virginia as of October 2005.  At the time the study was started, there 
were 34,694 physicians with M.D. or D.O. degrees in the Virginia Department of Health 
Professions database, available online at http://www.vahealthprovider.com/search.asp.  A 
database containing each physician’s name, primary practice address, license number, 
date of issue, expiration date, specialties, and degree (M.D., D.O., Intern/Resident) was 
created in Microsoft Access.  Of the 34,694 physicians, 21,835 had Virginia addresses, 
and 797 had licenses that were expired.  There were 4,635 intern/residents.  Those with 
generalized specialties numbered 14,411.  
Inclusion/Exclusion Criteria 
Doctors of Osteopathy were included in the sampling frame as they have full 
prescribing power.  Interns and residents were excluded since they do not yet have 
complete autonomy in decision making.  Because of the nature of the patient cases 
depicted in the questionnaire, only generalized specialties most likely to see the patients 
presented were included in the sampling frame.  Those specialties included were: general 
practice, family practice, internal medicine, emergency medicine, public health, and 
preventative medicine. 
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Sample Size 
The required sample size for a margin of sampling error of (5% for the population 
size of 14,411 was 375.  Based on a predicted response rate of 25-30%, 1248-1500 
physicians were needed in order to yield the sample size.  Equation 1 was used for this 
calculation. 
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In the above equation, Ns is the required sample size, Np is the population size, p is the 
proportion of the population expected to choose one of a two-response item, B is the 
acceptable amount of sampling error, and C is the z-statistic associated with the chosen 
confidence interval (Dillman, 2000).  For this project, p was assumed to be 0.5, the 
lowest variability in responses, which would increase the needed sample size.  An 
accepted error rate of +/-5% was used, and 1.96 was used as the z-statistic corresponding 
with a 95% confidence interval.  Because of budget and labor constraints, however, a 
random sample of 1008 physicians was used, so that equal numbers of each of the 24 
versions of the questionnaire were sent out. 
The random sample is expected to reflect the population of actively licensed 
physicians in general practice areas in the Commonwealth of Virginia with respect to 
demographics and generalizability of results. 
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Development of Questionnaire 
The questionnaire was designed to gather information on physicians’ prescribing 
decisions, opinions about package insert excerpts, sources used for drug information, 
ideas about addiction and drug dependence, and various demographics.  The 
questionnaire presented physicians with four patient cases, each associated with a 
different package insert excerpt, and a series of five questions related to each case.  The 
final section was designed to ascertain information on sources used for drug information, 
the importance of certain factors in making prescribing decisions, ideas about drug 
dependence and addiction, and to obtain demographic information.  A complete version 
of the final questionnaire can be found in Appendix C. 
Section 1: Patient Case Scenarios 
The first section of the questionnaire presented physicians with four patient case 
scenarios and a package insert excerpt.  Patient case scenarios were used to indirectly 
assess how various patient characteristics might also influence prescribing decisions.  
Patient characteristics included the type of pain and history of substance abuse.  
The first patient characteristic was the type of pain being treated.  The four levels 
for type of pain were: 
1) Acute, represented by a recent broken ankle, 
2) Chronic, malignant/cancer pain, 
3) Chronic non-malignant pain of known origin (CNMK), represented by 
osteoarthritis, and  
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4) Chronic non-malignant pain of unknown origin (CNMU), represented by lower 
back pain of unknown etiology. 
Levels for pain type were initially acute and chronic.  However, chronic pain cannot 
easily be represented by one condition, so three levels for chronic pain were defined.  
Common complaints were chosen to represent chronic, non-malignant pain conditions. 
The second patient characteristic varied in the case scenarios was history of 
substance abuse.  There is a wide spectrum of substance abuse history possible.  The 
length of time since a person has used, whether or not they are in a controlled 
environment, extent of use, type of substance/s used, and relapse can all affect a 
physician’s view of the risk of abuse for a patient.  However, this was not the focus of 
this study, and in order to maintain a reasonable number of variables, the patient’s history 
of substance abuse was represented by one of three levels: 
1) Current, described as occasional use for recreational purposes 
2) Past, indicated by a previous use but not within the last 5 years, 
3) No history of substance abuse. 
Because patient demographics were not variables of particular focus in this study, the 
patient’s age, sex, and ethnicity were kept constant.  This also kept the number of 
variables at a more manageable level.  Based on United States Census Bureau 
information from 2000, the patient was a 38 year-old Caucasian male.  The four levels of 
pain type and three levels of substance abuse history required a total of twelve patient 
case scenarios in order for all combinations to be used.  The patient case scenarios used 
in the final questionnaire versions are available as Appendix D.  A package insert excerpt 
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representing a medication previously prescribed to the patient followed each case 
scenario.  Package inserts contained three variables: 
1) Warning strength, classified as either “strong” or “not strong,” 
2) Advice, which was either present or not present, 
3) Definitions of terminology used in the package insert, also considered either 
present or not present.   
Each package insert was classified on these variables a priori independently by three 
researchers (LBP, PWS, SEH).  Strength of warning was initially classified as “mild, 
moderate, or strong” but later collapsed into two categories.  Initially, definitions were 
counted, but this was also collapsed into two categories of “present” and “not present.” 
Criteria for classification were as follows: 
1) Strength of the warning:  Specifically, the statement regarding the dependence 
potential of the drug. 
Mild: Groups the drug in question with other drugs, taking focus off the drug 
itself.  Looked for phrases such as:  "Drugs in this class have been associated with 
dependence"  "Like other drugs in this class, Drug X may cause dependence" 
Moderate:  Implicates the drug itself as the cause of dependence, but does not 
indicate any severity.  Phrases include "Drug X has been associated with 
dependence" "Drug X can cause dependence" 
Strong:  Implicates the drug at hand with severe or debilitating dependence, or has 
high dependence potential.  Phrases include "Drug X has been associated with 
severe dependence" "Drug X can cause dependence resulting in 
severe/debilitating social/occupational dysfunction" and the like. 
 
2) Direct advice given: Evaluates whether or not the information tells a physician 
what to do in a specific situation.  
Yes: The information uses the imperative/command form of a verb.  For example 
"Do this in this situation" or "Do not do thus and so" 
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No:  No direct advice given.  This includes "suggestions" that do not directly tell a 
physician what do to.  For example, "Those with a history of substance abuse may 
be at higher risk for psychic dependence",  "Withdrawal symptoms may occur if 
the drug is discontinued abruptly" or "Symptoms of withdrawal may be 
relieved/caused by administration of..." 
 
3) Definitions:  Evaluation of definitions for terminology of interest.  A "point" is 
given for each term defined or described.  Terms include: addiction, drug 
dependence, physical dependence, psychic/psychological dependence, tolerance, 
and withdrawal.   
 
Based on three variables with two levels each, eight package insert excerpts were used to 
include all possible combinations. The finalized versions of the package insert excerpts 
are detailed in Appendix E of this document. 
As described above, twelve patient case scenarios and eight package insert 
excerpts were used.  In order to ensure that all 96 combinations of patient case scenarios 
and package inserts were used, 24 versions of the questionnaire, each with four different 
combinations, were created.  Each questionnaire version contained a patient case with 
each type of pain, and at least one each of the three levels of substance abuse history.  
Likewise, each version had at least one strong warning, at least one package insert 
containing advice, and at least one package insert with definitions of terminology.  A 
4-point Likert scale was used with points labeled “not at all, not very, somewhat, and 
definitely.”  Survey respondents tend to gravitate toward middle responses (Dillman, 
2000).  Because the questions asked here were thought more likely to cause indecision, 
which would render those responses useless for data analysis, a neutral response was not 
provided as an option. 
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In addition to the three measures of prescribing decisions, physicians were asked 
two additional questions at the end of each scenario about the package insert excerpts to 
assess physician-rated usefulness and warning strength.  The first was how useful the 
package insert information was, and was measured with the same Likert scale described 
above.  The second question asked physicians to classify which Controlled Substance 
schedule was most appropriate for the drug. 
Section 2: Sources Consulted for Drug Information 
Information on sources used for drug information was presented as a grid, where 
physicians were to select how often they used various sources for drug abuse and 
dependence information and for other information.  Figure 4.1 shows the grid used. 
 
Figure 4.1  Grid used for gathering information about sources consulted by physicians 
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Section 3: Factors in Clinical Decision-Making 
In this section, physicians were overtly asked to rate the importance of various 
factors in their clinical decision-making.  The factors represented the patient and package 
insert characteristics presented in the patient case scenarios.  They were: 
1) Controlled Substance schedule, 
2) Definitions of terminology provided in the package insert, 
3) Patient’s history of substance abuse, 
4) Presence of clinical advice in package insert information, 
5) Type of pain being treated, 
6) Warning strength in package insert information. 
 
A 4-point Likert scale with points labeled “not at all important, somewhat unimportant, 
somewhat important, and very important” was used.  Again, no neutral response option 
was provided. 
Section 4: Definitions of Addiction and Drug Dependence 
To characterize how physicians perceive the terms “addiction” and “drug 
dependence,” a list of seven possible symptoms or conditions was presented.  These 
were: 
1) Abuse, 
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2) Craving, 
3) Drug-seeking behavior, 
4) Physical dependence, 
5) Psychological dependence, 
6) Tolerance, 
7) Withdrawal. 
Physicians were asked to choose which were necessary for drug dependence to exist, and 
again for addiction.  Respondents could choose all that apply. 
Section 5: Demographic Information 
Demographic information collected included physician gender, initial year of 
licensure, medical specialty, estimated percentage of patients with a known history of 
substance abuse, and region of practice.  Initial year of licensure, medical specialty, and 
estimated percentage of patients with a known history of substance abuse were open-
ended to allow for more specific data collection.  Region of practice was presented as a 
list of eight areas corresponding with zones indicated on a map of Virginia.  The regions 
were labeled: 
1) Northern,  
2) Western,  
3) Central,  
4) Tidewater,  
5) Southern,  
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6) Southwestern,  
7) Northern Neck,  
8) Eastern Shore. 
Pilot of Questionnaire 
The development and pre-testing of the questionnaire occurred in the following 
stages: 
1) Review by committee: The review committee consisted of the five members of 
the dissertation advisory committee plus one other survey researcher and a 
practicing primary care physician. This committee, consisting of experts in the 
areas of substance abuse research, survey methodology, clinical research, and 
practice, allowed for feedback from a diverse background of expertise.   
2) Survey feedback:  A convenience sample of 5 physicians who agreed to the task 
was asked to fill out the questionnaire and provide feedback upon completion.  
This feedback was used to further polish the items and format of the 
questionnaire.  Responses on these questionnaires were not recorded for use in the 
data analysis of the final survey, as the purpose of the procedure was to gain 
insight into the strengths and weaknesses of the questionnaire itself.  Comments 
received by these physicians are provided in Appendix F of this document. 
3) Final review by committee: A final review by the dissertation committee was used 
to uncover typographical errors, incorrect numbering, and any other previously 
overlooked mistakes before mailing occurred. 
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4) Cover letter: A cover letter explaining the general purpose of the survey and 
stressing the importance and appreciation of response and assuring anonymity 
was written and approved by the committee.  The finalized cover letter for the 
first mailing is represented as Appendix G of this document. 
5) In order to easily distinguish between versions of questionnaires upon return, four 
different colors of paper were used for the covers, and six combinations of 
location for the correspondence address and VCU Medical Center logo were used. 
Survey Process 
After approval was granted by the Institutional Review Board (IRB), the Tailored 
Design Method suggested by Dillman (2000) was implemented.  This method involves 
multiple contacts to the selected sample of physicians and has been shown to increase 
response rate (Dillman, 2000).  Each of the randomly selected physicians was assigned a 
number from 0001 to 1008.  There were a total of four contacts.  The first mailing packet 
contained four items: a cover letter, a questionnaire, a stamped, addressed return 
envelope, and a response postcard.  The postcard, shown in Figure 4.2, included just the 
physician’s code number and check boxes stating, “I have completed and returned the 
questionnaire,” and “I do not wish to participate in this survey.”  This postcard was also 
stamped and addressed for ease of mailing.  The cover letter and questionnaire 
instructions indicated that the postcard was to be returned separately from the 
questionnaire. 
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Figure 4.2  Return postcard 
 
 
The separate mailing of the questionnaire and the postcard both maintained total 
anonymity and allowed for tracking of respondents.  Physicians who mailed the return 
postcard did not receive a replacement questionnaire in the third mailing, as described 
below. 
The second mailing occurred two weeks after the questionnaire packet was 
mailed.  A reminder/thank you postcard, shown in Figure 4.3, was sent to each physician 
with the exception of refusals (i.e., those who had returned the postcard with the box 
checked next to “I do not wish to participate in this survey”) and to whom the initial 
mailing was returned as undeliverable. 
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Figure 4.3  Thank you/reminder postcard 
 
 
This postcard thanked those who completed the questionnaire and served as a reminder to 
those who had not yet responded.  
The third mailing was sent three weeks later to those who had not yet responded 
and included a revised cover (Appendix H) letter and replacement questionnaire was sent 
to those who had not yet responded.  The fourth mailing was another reminder/thank you 
postcard sent another three weeks later.  This technique of multiple contacts was 
employed to improve response rates as discussed by Dillman (2000). 
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Data Entry and Analysis 
Questionnaires were opened in batches of 10 or more at a time so that no postcard 
returned could be matched with a questionnaire, further maintaining anonymity.  
Questionnaires returned more than 4 weeks after the final mailing were not used in data 
analysis.  As postcards were returned, the matching entry in the database was coded with 
a “Y” for those who responded, an “N” for those who indicated they did not wish to 
participate in the survey, and an “R” for those returned as undeliverable. 
SPSS for Windows 13.0 statistical software was used to analyze the data.  A 
questionnaire was considered complete if at least three of the patient cases were answered 
and if responses were provided for sections 2, 3, 4, and at least 3 of the 5 questions in 
section 5.  Sections 2-5 consisted of the information about sources used for drug 
information, importance of factors in making clinical decisions, definitions of addiction 
and drug dependence, and demographics. 
Categorical variables were coded as numbers, while numerical variables were 
recorded directly.  Indicator variables were created for categorical variables with more 
than two categories.  The codebook is available as Appendix I of this document. 
Region of practice was collapsed into three categories: Southwestern, urban, and 
other rural.  Southwestern Virginia was used as the reference group because it was a 
region of interest.  Physician specialty or medical discipline was collapsed into four 
categories: family practice, internal medicine, emergency medicine, and other.  
Emergency medicine was used as the reference group for this set of indicator variables.  
For type of pain, chronic, non-malignant pain of unknown etiology (CNMU) was the 
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reference group because the other types of pain had a known cause.  For substance abuse 
history, “none” was the reference group as the other levels of the variable represented at 
least some history of substance abuse. 
Interaction terms were created for three sets of variables: history of substance 
abuse with type of pain, history of substance abuse with warning strength, and type of 
pain with warning strength.  Because the indicator variables were used to create the 
interaction products, there were a total of 11 interaction products entered into the model: 
six representing history of substance abuse with type of pain, two representing history of 
substance abuse with warning strength, and three representing type of pain with warning 
strength.  These were added into the model in three separate blocks. 
Demographic information was characterized using descriptive statistics as 
appropriate. Frequencies were reported for categorical variables of gender, specialty, and 
region of practice.  For the continuous variables of initial year of licensure and 
percentage of patients with a known history of substance abuse, mean and standard 
deviation or median and range were used as determined by normality.   
Frequencies were reported for the terms physicians associated with drug 
dependence and addiction, and for sources used for drug information.   
 
Missing data: 
Fortunately, the large majority of questionnaires returned were filled out 
completely enough for analysis.  Because of the small numbers of missing data on each 
variable, the following techniques were used to deal with missing data: 
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• Initial year of licensure was replaced with the median 
• Sources grid:  For the grid concerning sources used for drug information, it was 
assumed that missing data were indicative of a “never” response, and was 
therefore transformed in SPSS from “system missing” to “0.” 
• For case scenario questions: case scenarios left unanswered were dropped. 
Regression Models 
Linear regression models were used to describe the effect of the physician, 
patient, and package insert characteristics on physician prescribing decisions.  Four 
models were evaluated, one for each of the prescribing decision measures, and one for a 
sum scale measurement for willingness to prescribe.  The last would be evaluated only if 
the three individual measures were highly correlated with each other and had a reliability 
of α ≥ 0.7.   
The major dependent variable was a decision to prescribe medication.  This was 
measured in three ways: 
1) Comfort level with a prior physician’s choice 
2) Likelihood of refilling the prescription 
3) Likelihood of choosing the drug if the respondent was the first physician to see 
the patient. 
Each model is represented by equation 2: 
 
 Ŷ = B1X1 + B2X2 + … + BkXk + B0    (2)  
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In the above equation, Ŷ is the predicted y-value, B is an unstandardized regression 
coefficient, k is the number of variables in the model, and B0 is the y-intercept (Cohen 
and Cohen, 2003).  Therefore, in the initial models, Ŷ represents the measure of 
prescribing decisions (comfort level, refilling, and first-time prescribing), and in the 
fourth model, it would represent the measure of willingness to prescribe.  The B-values 
are the unstandardized regression coefficients for each of the physician characteristics, 
patient variables, and package insert variables.   
Independent variables were blocked together into three categories: physician 
characteristics, patient characteristics, and package insert excerpt characteristics, as 
described above in the measures section.  The first block of predictors entered into the 
model was that of physician characteristics, which included year of initial licensure, 
gender, region of state, medical discipline, and estimated percentage of patients with a 
known history of substance abuse.  The second block of independent variables for the 
model included the patient characteristics, which were type of pain and history of 
substance abuse.  The third block of predictors was made up of the package insert 
variables.  This was the final block of main effects in the models because it was the focus 
of the project and in hierarchical terms, its R2 value indicates the amount of variance the 
package insert information provides over and above the other main effects.  Strength of 
warning was either “strong” or “not strong,” a presence or absence of advice, and 
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presence or absence of definitions given in each excerpt.  The interaction terms were 
added as fourth, fifth, and sixth blocks.
  73
5 Results 
CHAPTER 5 
Results 
Response Rate 
Of 1008 questionnaires mailed, 155 were returned undeliverable and 7 were 
returned stating “retired” on the postcard, leaving an actual sample size of 846.  A total of 
273 questionnaires met the criteria for a complete questionnaire and were used for 
analysis.  Based on the sample size of deliverable questionnaires, the response rate was 
32.3%.  Eighty-three (9.8%) physicians returned the postcard with the box labeled “I do 
not wish to participate in this survey” checked.  Interestingly, more questionnaires were 
returned than postcards.  Although 277 questionnaires were returned before the cut-off 
date of April 3rd, 2006, only 246 postcards indicating the questionnaire had been 
completed were received.  Figure 5.1 shows the numbers of questionnaires and postcards 
returned.  The postcards were the only means of tracking responders and non-responders.  
Because more questionnaires than postcards were returned, some responders’ 
characteristics were accounted for as non-responders. 
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Figure 5.1  Flowchart of questionnaire responses 
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Responders and Non-Responders 
 Although responders were tracked to prevent mailing second questionnaires to  
responding physicians, postcards identifying the responders were separate from returned 
questionnaires, maintaining anonymity of responders.  Characteristics of responders and 
non-responders were analyzed for significant differences on the variables of gender, 
region of practice, and initial year of licensure.  Table 5.1 displays these characteristics.  
Chi-square analysis revealed no statistically significant differences between responders 
and non-responders with respect to gender or region of practice.  Although year of 
licensure was a continuous variable, it was not normally distributed, dictating that a 
nonparametric test was more appropriate.  The Mann-Whitney U-test revealed that 
responders had been practicing significantly longer than non-responders, with initial year 
of licensure having median values of 1985 and 1992, respectively.  Initial year of 
licensure was also significant in the regression models, as discussed below.  Although the 
impact of the significant difference between non-responders and responders is unknown, 
it would be expected that the data would shift toward increased prescribing, since this 
was the case among responders. 
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Table 5.1  Characteristics of responders and non-responders 
Variable Responders Non-responders p-value 
Gender(%)   0.070 
     Male 74.4 66.1  
     Female 23.1 28.1  
     Unknown   2.5   5.8  
Region of practice (%)   0.360 
     Urban 65.9 67.2  
     Southwestern   9.9   7.0  
     Other non-urban 23.1 20.7  
     Unknown   1.1   5.1  
Year of licensure (median) 1985 1992 <0.001 
 
 
Responding physicians reported a median estimate of 5% of patients they see 
having a known history of substance abuse, ranging from 0%-100%.  The interquartile 
range was 2%-10%.  The one physician that reported 100% was an addiction medicine 
specialist.  One physician reporting 75% of patients with a known history of substance 
abuse participated in correctional facility work.  This information was written in as a 
comment by the respondents.  Other respondent comments can be found in Appendix J of 
this document.  
Objective 1: Definitions of Addiction and Dependence 
To gather information about physicians’ impressions of the terms “addiction” and 
“drug dependence,” physicians were provided with a list of characteristics and asked to 
check any features they felt were necessary for the condition in question to exist.  These 
characteristics included: abuse, craving, drug-seeking behavior, physical dependence, 
psychological dependence, tolerance, and withdrawal.  Table 5.2 shows the frequency 
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with which each was chosen.  More physicians associated abuse, craving, drug-seeking 
behavior, psychological dependence, and withdrawal with addiction than with drug 
dependence, while more physicians felt that physical dependence and tolerance were 
necessary for drug dependence.   
 
Table 5.2  Frequency of chosen factors necessary for addiction and drug dependence 
Term Drug dependence 
Frequency (%) 
Addiction 
  Frequency (%) 
Abuse  89 (32.6) 210 (76.9) 
Craving 121 (44.3) 236 (86.4) 
Drug-seeking behavior 116 (42.5) 241 (88.3) 
Physical dependence 207 (75.8) 187 (68.5) 
Psychological dependence 198 (72.5) 217 (79.5) 
Tolerance 175 (64.1) 169 (61.9) 
Withdrawal 175 (64.1) 183 (67.0) 
 
 
For the conditions of addiction and drug dependence, the terms physical 
dependence, psychological dependence, tolerance, and withdrawal were chosen as 
necessary by more than 50% of physicians.  Abuse, craving, and drug-seeking behavior, 
however, were chosen by more than 50% of physicians for addiction but not for drug 
dependence. 
Objective 2: Sources Used for Drug Information 
Physicians were asked to rate the frequency with which they consult various 
sources for drug abuse and dependence information, and other drug information.  
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Frequency was defined as never (0), yearly (1), monthly (2), weekly (3), or daily (4).  
shows the mean and median frequency for each source consulted for drug abuse and 
dependence information and other drug information. 
 
 
Table 5.3  Sources consulted by physicians 
Source Drug Abuse Info
Mean (median) 
Other Info 
Mean (Median)
Manufacturer 0.15 (0) 0.39 (0) 
Drug Information Center 0.21 (0) 0.33 (0) 
Internet 1.03 (0) 1.55 (2) 
Package Insert 1.32 (1) 1.95 (2) 
Personal Digital Assistant 0.98 (0) 1.54 (0) 
Pharmacist 1.27 (1) 1.96 (2) 
Physicians’ Desk Reference 1.61 (1) 2.39 (3) 
Other 0.40 (0) 0.49 (0) 
 
As with the measure of factor importance, a mean was calculated for the 
consulted source even though the frequency is on an ordinal scale.  The mean was used 
only for ranking purposes.  For both drug abuse/dependence and other information, the 
Physicians’ Desk Reference (PDR) was the most frequently used source.  Pharmacists 
and package inserts were the next highest ranking for both types of information.  
Manufacturers and drug information centers ranked the least frequently used.  For all 
sources consulted, the frequency was lower for drug abuse/dependence information than 
for other information, and the overall frequency of sources consulted was low.  Most 
physicians who marked a frequency other than “never” for the “Other” category did not 
write in their other sources.  Other sources reported by physicians listed in Table 5.4. 
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Table 5.4  List of “Other” sources consulted by physicians for drug information 
• Poison Control Center 
• Pharmacology textbook 
• UpToDate online 
• Primary literature 
• “Drug reps” 
• “Medical students – PDA by proxy?” 
• “Unbiased sources” 
 
Some of these sources could be classified in other categories:  UpToDate could be 
classified as an internet source, and drug sales representatives could be classified as 
manufacturer contact. 
Objective 3: Regression Models 
Four regression models were evaluated.  The dependent variables were all 
measures of physician prescribing decisions: comfort with the prior physician’s choice, 
likelihood of refilling the prescription, likelihood of prescribing if the respondent was the 
first physician to see the patient, and willingness to prescribe.  Answers to three questions 
pertaining to prescribing decisions were on a 4-point Likert scale: not at all (0), not very 
(1), somewhat (2), or definitely (3).  The dependent variable in the fourth model, 
“willingness to prescribe,” was created as a sum score from the first three variables, 
which were highly correlated with each other.  Reliability testing for the scale resulted in 
a Crohbach’s alpha of 0.944.  The correlation coefficients for comfort level with refill 
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likelihood and first prescription likelihood were 0.844 and 0.862, respectively.  The 
correlation coefficient for refill likelihood and first prescription likelihood was 0.843. 
For each model, the same six blocks of predictors were entered for hierarchical 
regression analysis.  Table 5.5 summarizes the variables in the blocks of predictors 
entered into each model. 
 
Table 5.5  Summary of variables entered into regression models 
Block 1: Physician Characteristics 
 Gender 
 Initial year of licensure 
            Estimated percent of patients with a known history of substance abuse 
 Practice region (Southwestern, urban, other rural) 
 Medical discipline (emergency, family practice, internal medicine, other) 
Block 2: Patient Characteristics 
 Type of pain being treated (acute, cancer, CNMK, CNMU) 
 History of substance abuse (none, past, current) 
Block 3: Package Insert Characteristics 
 Strength of warning in package insert (strong, not strong) 
 Presence of direct advice in package insert (present, not present) 
 Presence of definitions in package insert (present, not present) 
Block 4: Interaction terms for type of pain with history of substance abuse 
Block 5: Interaction terms for type of pain with warning strength 
Block 6: Interaction terms for history of substance abuse with warning strength 
 
For nominal variables with more than 2 categories, indicator variables were 
created.  For a physician’s practice region, the reference group was Southwestern 
Virginia, and indicator variables were designated for urban and other rural.  For medical 
discipline, emergency medicine (EM) was the reference group, with indicator variables 
created for family practice (FP), internal medicine (IM), and other.  Type of pain was in 
reference to chronic, non-malignant pain of unknown etiology (CNMU) with indicator 
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variables for acute, cancer, and chronic, non-malignant pain of known etiology (CNMK).  
For the history of substance abuse, the reference group was “none,” and indicator 
variables were created for past history and current use. 
 
All four models displayed overall significance at p<0.001.  For all four models, 
the blocks for physician, patient, and package insert characteristics, and interactions 
between pain and history of substance abuse were significant.  The blocks for interactions 
between warning strength with type of pain and with history of substance abuse were not 
significant in any model.  Table 5.6 shows the overall adjusted R2, R2 change, and p-
values representing the significance for each block of predictors for the four models. 
 
Table 5.6  Statistics for predictor blocks for four initial regression models 
 Comfort model ∆R2 (p-value) 
Refill model 
∆R2 (p-value) 
1st doctor model 
∆R2 (p-value) 
Willingness 
model 
∆R2 (p-value) 
Physician 
characteristics 0.036 (<0.001) 0.021 (0.006) 0.033 (<0.001) 0.032 (<0.001) 
Patient 
characteristics 0.362 (<0.001) 0.377 (<0.001) 0.348 (<0.001) 0.339 (<0.001) 
Package insert 
characteristics 0.031 (<0.001) 0.023 (<0.001) 0.032 (<0.001) 0.031 (<0.001) 
Interactions:  
type of pain with 
history 
0.018 (<0.001) 0.010 (0.009) 0.018 (<0.001) 0.016 (<0.001) 
Interactions:  
type of pain with 
warning strength 
0.002 (0.293) 0.002 (0.250) 0.001 (0.513) 0.002 (0.358) 
Interactions: 
history with 
warning strength 
0.001 (0.526) 0.003 (0.112) 0.000 (0.756) 0.001 (0.423) 
Adjusted R2 0.435 0.420 0.417 0.466 
 
 
  
82
Because the predictor blocks for interactions between warning strength with type 
of pain and history of substance abuse were not significant, the individual regression 
coefficients were not further examined.  Appendix K contains unstandardized regression 
coefficients, standard errors, and p-values for all of the predictors in significant blocks for 
the four models. 
Within the block of physician characteristics, neither gender nor estimated 
percentage of patients with a history of substance abuse was significant in any model.  
Initial year of licensure and medical discipline were significant for all four models.  
History of substance abuse and type of pain being treated were significant in the patient 
characteristics blocks for each model.  Warning strength and the presence of definitions 
were both significant in all four models.  The presence of advice in the package insert 
was significant for all but the refill model.  Further exploration of the models follows. 
Model 1: Comfort Level of Prior Prescription 
For the first model, the dependent variable of physician prescribing decisions was 
measured by the question “How comfortable are you with the prior physician’s choice of 
medication for this patient?”  The overall adjusted R2 indicates that 43.5% of the variance 
in the level of comfort with a prior physician’s choice is explained by the physician, 
patient, package insert, and interaction terms entered into the initial model.  Because the 
blocks for interaction terms for warning strength with type of pain and substance abuse 
were not significant, they were not included in the final model.  The final model, then, 
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consisted of all predictors in the first four blocks described above.  Based on the 
unstandardized regression coefficients, the equation for the final model is: 
 
(5.1) 
 
Abbreviations used in the above equation are listed in Table 5.7  Estimated percent of 
patients with a known history of substance abuse was not included in the equation 
because the regression coefficient was 0.000.  
 
Table 5.7  Abbreviations used in regression equation 5.1 
• Gen = physician gender 
• §Yr = initial year of physician licensure 
• Urb = urban region of practice 
• Rural = other rural practice region 
• §FP = family practice specialty 
• §IM = internal medicine specialty 
• §Other = other medical discipline 
• §Acute = acute pain 
• §Cancer = cancer pain 
• CNMK = chronic, non-malignant pain of known etiology 
• §Past = past history of substance abuse 
• §Curr = current history of substance abuse 
• §Str = warning strength in package insert 
• §Adv = advice in package insert 
• §Def = definitions in package insert 
• Ac*past = acute pain with a past history of substance abuse 
• Ac*curr = acute pain with current recreational substance use 
Comfort level =  
-0.093(gen) +0.11(yr) +0.091(urb) +0.166(rural) -0.335(FP) -0.342(IM) -0.306(other) 
+1.125(acute) +1.437(cancer) +0.243(CNMK) -0.442(past) -0.500(curr) -0.270(str) -
0.169(adv) -0.196(def) -0.355(ac*past) +0.198(ac*curr) +0.414(can*past) 
+0.364(can*curr) +0.313(CNMK*past) +0.086(CNMK*curr) -21.069 
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Table 5.7 Abbreviations used in regression equation 5.1 (continued) 
• §Can*past = cancer pain with a past history of substance abuse 
• §Can*curr = cancer pain with current recreational substance use 
• CNMK*past = CNMK with a past history of substance abuse 
• CNMK*curr = CNMK with current recreational substance use 
§ significant at p<0.05 
 
The physician characteristics explain 3.6%, and patient characteristics explain 
36.2% over and above the physician characteristics, based on the change in R2.  The 
package insert characteristics of warning strength, advice, and definitions, then, explain 
an additional 3.1%, while the interactions between pain type and substance abuse history 
add an additional 1.8% to the model.  The p-values for the change in R2 were all <0.001.  
Physicians who have been more recently licensed are more comfortable with a 
prior physician’s choice.  Acute and cancer pain significantly increased comfort level 
when compared to chronic, non-malignant pain of unknown eitiology (CNMU).  Chronic, 
non-malignant pain of known etiology (CNMK) did not significantly affect comfort level 
when compared to CNMU.  Past or current history of substance abuse decreased comfort 
level compared to patients having no history of substance abuse.   Strong warnings, the 
presence of advice, and the presence of definitions in the package insert excerpts 
decreased physician comfort level with the prior physician’s choice of medication.   
The reference groups for pain type and substance abuse history were CNMU and 
no history of substance abuse.  Two interaction terms were significant in the initial model 
and were entered into the final model.  The term for cancer pain and current history of 
substance abuse became non-significant in the final model; however, the interaction 
product for cancer pain and past history of substance abuse remained significant.  This 
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indicated that the importance of the patient’s history of substance abuse was dependent 
on the type of pain being treated.  In this model, cancer pain, regardless of history of 
substance abuse, increases physicians’ comfort level when compared to a patient with 
CNMU with no history of substance abuse.  In other words, even though past and current 
history of substance abuse decrease comfort level, this becomes less important if the 
patient is experiencing cancer pain. 
Model 2: Likelihood of Refilling 
The second measure of physician prescribing decisions asked the question “How 
likely are you to refill this prescription?”  The initial model (i.e. with all six blocks of 
predictors) for this question showed an overall adjusted R2 of 0.418, and the final model 
had an adjusted R2 of 0.416.  Physician characteristics explain just 2.1% in this model, 
with patient characteristics adding 37.7%.  Package insert characteristics contribute an 
additional 2.3% over and above physician and patient characteristics.  Interactions 
between pain type and substance abuse history, while statistically significant, add another 
1.0% of explanation of variance in frequency of refilling. 
The resulting equation for the final model is depicted in equation 5.2. 
(5.2) 
Likelihood of refilling the prescription = 
0.040(gen) +0.011(yr) -0.002(%) +0.104(urb) +0.147(rural) -0.177(FP) -
0.161(IM) -0.193(other) +0.901(acute) +1.585(cancer) +0.290(CNMK) -
0.281(past) -0.374(curr) -0.252(str) -0.103(adv) -0.153(def) -
0.491(ac*past) -0.113(ac*curr) +0.244(can*past) +0.176(can*curr) 
+0.113(CNMK*past) +0.001(CNMK*curr) -21.392 
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Table 5.8 lists the abbreviations used in equation 5.2 and indicates which 
regression coefficients were significant. 
 
Table 5.8  Abbreviations used in regression equation 5.2 
• Gen = physician gender 
• §Yr = initial year of physician licensure 
• % = estimated percent of patients with known substance abuse history 
• Urb = urban region of practice 
• Rural = other rural practice region 
• §FP = family practice specialty 
• §IM = internal medicine specialty 
• Other = other medical discipline 
• §Acute = acute pain 
• §Cancer = cancer pain 
• §CNMK = chronic, non-malignant pain of known etiology 
• §Past = past history of substance abuse 
• §Curr = current history of substance abuse 
• §Str = warning strength in package insert 
• Adv = advice in package insert 
• §Def = definitions in package insert 
• §Ac*past = acute pain with a past history of substance abuse 
• Ac*curr = acute pain with current recreational substance use 
• Can*past = cancer pain with a past history of substance abuse 
• Can*curr = cancer pain with current recreational substance use 
• CNMK*past = CNMK with a past history of substance abuse 
• CNMK*curr = CNMK with current recreational substance use 
§ significant at p<0.05 
 
Reference groups for those predictors with indicator variables remained the same as in 
the first model.  For pain, CNMU was the reference group, for physician specialty, 
emergency medicine, and for history of substance abuse history, “no history” was used. 
As in the first model (comfort model), more recent licensure indicates that a 
physician is more likely to refill the prescription presented in the case scenario.  Family 
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practitioners and internists are less likely to refill compared to emergency physicians.  
Not surprisingly, both acute and cancer pain increase likelihood of the physician refilling 
the prescription.  CNMK was also significant in this model (p=0.029) but not for any 
other model.  Past and current substance abuse histories again prove to have a negative 
effect on physician prescribing, as do strong package insert warnings and presence of 
definitions.  The interaction for acute pain with a past history of substance abuse in this 
model was also significant, again suggesting that the importance of substance abuse 
history depends on the type of pain being treated.  In this model, the interaction suggests 
that physicians are less likely to refill a prescription for acute pain if someone has a past 
history of substance abuse than they are for a patient with CNMU and no history. 
Model 3: Likelihood of First Time Prescribing 
The third measure of physician prescribing decisions was based on the question 
“how likely would you be to prescribe this medication if you were the first physician to 
see this patient?”  In this model, the adjusted R2 indictated that 41.8% of the variance in 
first prescribing could be attributed to the variables in the final model.  Again, various 
aspects of physician, patient, and package insert characteristics proved to be important, as 
did interaction terms for pain type and substance abuse history.  The final model is 
represented in equation 5.3.  Table 5.9 defines abbreviations used and indicates 
statistically significant variables. 
  
88
 
(5.3) 
Table 5.9  Abbreviations used in regression equation 5.3 
• Gen = physician gender 
• §Yr = initial year of physician licensure 
• % = estimated percent of patients with known substance abuse history 
• Urb = urban region of practice 
• §Rural = other rural practice region 
• §FP = family practice specialty 
• §IM = internal medicine specialty 
• Other = other medical discipline 
• §Acute = acute pain 
• §Cancer = cancer pain 
• CNMK = chronic, non-malignant pain of known etiology 
• §Past = past history of substance abuse 
• §Curr = current history of substance abuse 
• §Str = warning strength in package insert 
• Adv = advice in package insert 
• §Def = definitions in package insert 
• §Ac*past = acute pain with a past history of substance abuse 
• Ac*curr = acute pain with current recreational substance use 
• §Can*past = cancer pain with a past history of substance abuse 
• Can*curr = cancer pain with current recreational substance use 
• CNMK*past = CNMK with a past history of substance abuse 
• CNMK*curr = CNMK with current recreational substance use 
§ significant at p<0.05 
 
As in the first two models, more recent year of licensure is significant.  The 
interpretation for this model is that more recently licensed physicians would be more 
likely to prescribe the drug if they were the first to see the patient presented in the case 
First prescribing likelihood = 
-0.081(gen) +0.012(yr) +0.002(%) +0.132(urb) +0.231(rural) -0.181(FP) -
0.239(IM) -0.205(other) +1.143(acute) +1.389(cancer) +0.181(CNMK) -
0.370(past) -0.395(curr) -0.276(str) -0.175(adv) -0.175(def) -0.507(ac*past) -
0.051(ac*curr) +0.376(can*past) +0.273(can*curr) +0.244(CNMK*past) -
0.019(CNMK*curr) -21.623 
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scenario than would physicians who have been practicing for a longer period of time.  In 
this model only, region had an impact.  The reference group for region was Southwestern 
Virginia.  The interpretation of this regression coefficient would be that compared to 
physicians in Southwestern Virginia, physicians in other rural areas are more likely to 
prescribe the drug as the first physician seeing the patient.  Family practice and internal 
medicine specialties had a negative impact when compared with emergency physicians, 
as did either current substance abuse or a past history of substance abuse.  Again, the 
presence of acute or cancer pain increased the likelihood of prescribing, and strong 
warnings, presence of advice, and definitions in package insert information decreased 
potential prescribing.  As in the first two models, likelihood of prescribing is also 
dependent on the interaction between type of pain and substance abuse history, and the 
impact of substance abuse history on prescribing is dependent on the type of pain being 
treated.  Here, a past history of substance abuse has a negative impact if the pain type is 
acute, but a positive impact if the patient is experiencing cancer pain as compared to a 
patient with no substance abuse history and CNMU.   
Model 4: Willingness to Prescribe 
All three previous dependent variables gauge a physician’s willingness to 
prescribe a drug for the case scenario presented.  In this final model, physician 
prescribing decisions were measured as a sum scale of the dependent variables in the first 
three models.  That is, a physician’s answers to the first three questions were added 
together to create a “willingness score.”  This was done after correlation and reliability 
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testing indicated that the three prior measures were highly correlated with one another.  
Correlation coefficients were all >0.80, and Cronbach’s alpha, a measure of reliability, 
was 0.944.  A higher score on the scale translated to being more willing to prescribe the 
drug.  The adjusted R2 for the final model indicated that 46.6% of the variance in 
willingness to prescribe could be explained by the variables in the model.  This 
composite dependent variable model explained between 3.1% and 4.9% more variance in 
physician prescribing than any of the individual dependent variables alone. 
Equation 5.4 represents the regression model for willingness to prescribe, and 
Table 5.10 shows abbreviations used in the equation and indicates significant variables. 
(5.4) 
Table 5.10  Abbreviations used in equation 5.4 
• Gen = physician gender 
• §Yr = initial year of physician licensure 
• % = estimated percent of patients with known substance abuse history 
• Urb = urban region of practice 
• Rural = other rural practice region 
• §FP = family practice specialty 
• §IM = internal medicine specialty 
• §Other = other medical discipline 
• §Acute = acute pain 
• §Cancer = cancer pain 
• CNMK = chronic, non-malignant pain of known etiology 
• §Past = past history of substance abuse 
• §Curr = current history of substance abuse 
• §Str = warning strength in package insert 
Willingness to prescribe= 
-0.134(gen) +0.034(yr) +0.327(urb) +0.546(rural) -0.693(FP) -0.742(IM) -
0.710(other) +3.170(acute) +4.411(cancer) +0.713(CNMK) -1.075(past) -
1.269(curr) -0.797(str) -0.448(adv) -0.524(def) -1.298(ac*past) +0.025(ac*curr) 
+1.034(can*past) +0.816(can*curr) +0.670(CNMK*past) 
+0.067(CNMK*curr)-64.092 
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Table 5.10 Abbreviations used in equation 5.4 (continued) 
• §Adv = advice in package insert 
• §Def = definitions in package insert 
• §Ac*past = acute pain with a past history of substance abuse 
• Ac*curr = acute pain with current recreational substance use 
• §Can*past = cancer pain with a past history of substance abuse 
• Can*curr = cancer pain with current recreational substance use 
• CNMK*past = CNMK with a past history of substance abuse 
• CNMK*curr = CNMK with current recreational substance use 
§ significant at p<0.05 
 
 
Results were similar to those of the other models.  Significant positive predictors 
of willingness to prescribe were initial licensure year and acute or cancer pain.  
Significant negative predictors were medical discipline other than emergency medicine, 
past substance abuse history or current substance abuse, strong package insert warnings, 
and advice or definitions in package inserts.  The interaction terms again indicated that 
willingness to prescribe for someone with a history of substance abuse depended on the 
type of pain being treated.  
Usefulness of Package Insert Information 
Physicians were asked to rate how useful they found the package insert 
information provided in making a clinical decision for the patient.  The same previously 
described 4-point Likert scale ranging from “not at all” to “definitely” was used.  
Physician ratings were collapsed into two categories as follows: not at all and not very 
were collapsed into a category called “not useful,” while somewhat and definitely were 
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collapsed into a “useful” category.  Chi-square for physician-rated usefulness and the 
presence of advice was performed and revealed a significant difference (Х2=11.43, 
p<0.001).   
Table 5.11 shows the frequencies of physician-rated usefulness for the presence or 
absence of advice provided in the package insert. 
 
 
Table 5.11  Contingency table for physician-rated usefulness and advice 
 Not useful Useful 
No advice 173 344 
Advice present 136 427 
 
 
Overall, more physicians rated package inserts as useful; however, the largest 
number of package inserts rated as useful were those with advice present.  The lowest 
number in the contingency table is the frequency of physicians rating a package insert 
with advice as not useful.  More physicians rated package inserts as not useful when there 
was no advice given than when advice was given; however, even when no advice was 
present in the package insert, more physicians rated it useful than not useful. 
Assessment of Instrument 
Although warning strength for each package insert excerpt was determined a 
priori, physicians were also asked to rate the warning strength by choosing the Controlled 
Substance Act (CSA) schedule that they felt was most appropriate for the medication 
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associated with the package insert excerpt provided.  Responses were collapsed into two 
schedule categories: schedule II and other.  Warnings determined as “strong” by the 
researchers should correspond with physicians choosing the highest control level, or CII.  
Table 5.12 shows the frequencies of schedule choice and pre-assigned warning strength. 
 
Table 5.12  Contingency table for researcher and physician-rated warning strength 
 Schedule II Other 
Strong 364 177 
Not strong 147 389 
 
 
Chi-square analysis revealed that the frequencies in each cell of the contingency table 
were not the same (Х2=171.54, p<0.001).  Examination of the contingency table 
frequencies suggests that researchers’ and physicians’ ratings agreed. 
A second assessment of the instrument examined regression coefficients with 
ranking of factor importance.  Physicians were overtly asked to rate the importance of 
factors in their clinical decision making.  If factors were rated as important by physicians, 
then the rankings of the importance of the factors should correspond with the rankings of 
the regression coefficients for the variables.   
 
 
Table 5.13 shows the mean response for the six factors and the regression 
coefficients for the corresponding variables in the final regression models.  It is important 
to note that while the scale on which the physicians rated the factors was ordinal, a mean 
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was calculated because it was being used only for the purpose of ranking the order of 
physician-rated importance of these variables.   
 
 
 
 
Table 5.13  Physician-rated importance of factors in clinical decision making and corresponding 
regression coefficients 
Regression Coefficients Factor in package insert Mean 
Physician 
Rating 
Comfort Refill 1st Doctor Scale
Type of pain being treated 
(cancer, acute) 
2.85  1.279
0.891
1.727
0.882
1.445 
1.018 
4.433
2.779
Patient’s history of substance 
abuse (current and past) 
2.79  -0.442
-0.426
-0.390
-0.201
-0.376 
-0.251 
-1.124
-0.717
Warning strength 1.93  -0.296 -0.274 -0.299 -0.850
Advice present 1.86  -0.173 -0.103 -0.169 -0.446
Definitions present  1.28  -0.181 -0.145 -0.166 -0.487
 
 
Generally, the physician ranking of factor importance corresponded with the ranking of 
the corresponding regression coefficient, with the exception of advice and definitions 
present.  Note that it is the magnitude of the regression coefficient that was taken into 
account because the sign indicated only the direction of the relationship to the dependent 
variable.  Based on both physician rating and regression coefficients, the type of pain 
being treated was clearly the most important factor, and warning strength was always 
higher than either advice or definitions present.  With respect to history of substance 
abuse, at least one regression coefficient ranked higher than warning strength in all cases.  
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6 Discussion and Conclusions 
CHAPTER 6 
Discussion and Conclusions 
Study Summary 
This survey study was designed to elucidate several issues surrounding drug 
abuse and dependence and physician prescribing behaviors, particularly as they relate to 
information provided in package inserts.  A total of 1,008 physicians practicing in the 
Commonwealth of Virginia in general medical disciplines were mailed a questionnaire 
packet.  Several contacts were employed to increase responses, resulting in an achieved 
response rate of 33.1%.  Items on the questionnaire addressed physician prescribing 
decisions, impressions of package insert information, ideas about addiction and drug 
dependence, sources consulted for drug information, and demographics.   
Research Objectives and Results 
Objective 1: Definitions of Addiction and Drug Dependence 
One of the objectives of this study was to describe how currently practicing 
physicians view the terms “addiction” and “drug dependence.”  Physicians more 
frequently associated physical dependence and tolerance with “drug dependence” than 
with “addiction,” suggesting that physicians tend to view drug dependence as a 
physiological state rather than the substance use disorder described in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM).  Abuse, craving, drug-seeking behavior, 
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psychological dependence, and withdrawal were more frequently associated with 
addiction than with drug dependence.  This points to physicians viewing addiction as the 
disease state of Drug Abuse or Drug Dependence as described in the DSM.  This 
disparity surrounding these terms can be confusing when reading package inserts that do 
not further explain what is intended by “drug dependence” or simply “dependence.”   
Because no specific statistical tests have been used to explore these data, the significance 
of these apparent differences in physicians’ ideas about these terms remains unknown.  
However, it is evident that many physicians do not appear to view the terms addiction 
and drug dependence equally. 
 
Objective 2: Sources of Drug Information 
A second objective of this study was to describe sources that physicians refer to 
for drug information.  Results showed that the three most consulted sources were the 
Physicians’ Desk Reference (PDR), package inserts, and pharmacists.  It is important to 
note that the PDR is in fact a collection of package inserts.  This being said, it appears 
that package inserts are an essential source of information for physicians, making 
standardized terminology imperative for providing information to prescribers.  
Pharmacists, another source of information for physicians, may also turn to the package 
insert for drug information, although this has not been explored in the current study.  
Overall, the frequencies with which physicians report consulting sources is low, 
with median values for most sources translating to “never” or “yearly.”  This begs the 
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question as to why physicians are not consulting drug information sources, particularly at 
a time when there are so many medications from which to choose? 
 
Objective 3: Regression Models 
Four regression models were used to examine physician prescribing decisions.  
These models were: comfort with a prior physician’s choice, willingness to refill the 
prescription, likelihood of prescribing as the first physician seeing the patient, and a sum 
score of the first three measures.  In all four regression models, the three blocks of main 
effects predictors were significant, as was the added predictor block of an interaction 
between type of pain and substance abuse history.  Two other blocks of interaction terms, 
one for warning strength with pain type and one for warning strength with substance 
abuse history, were not statistically significant. 
Initial year of licensure for physicians was consistently significant in all four 
models and indicated that more recent year of licensure had a positive impact on 
prescribing.  That is, physicians who were more recently licensed tended to be more 
comfortable with a prior physician’s choice, more likely to refill the prescription, and 
more likely to prescribe the drug if initially seeing the patient.  This was also reflected in 
the fourth model which showed that physicians who have been more recently licensed 
were more willing to prescribe the drug overall.  This could be attributed to their more 
recent education on pain management issues, or could be a reflection of deeper suspicion 
or concern about substance abuse and dependence by physicians who have had more 
years of experience. 
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Physician specialty was also found to be significant in all four models.  With 
respect to emergency physicians, family practice and internists were less likely to be 
comfortable with a prior physician’s choice, refill the medication, or to prescribe the 
medication as the first physician.  This was also demonstrated in the overall willingness 
model.  Emergency physicians may make decisions differently for several reasons.  First, 
they do not see the same patients on a regular basis.  While there are those who tend to 
use emergency rooms as primary care because of insurance issues, this is the exception 
and not the rule for most individuals.  Emergency physicians, then, do not tend to have an 
ongoing relationship with their patients.  The effect of this on prescribing decisions is 
unknown and was not explored in this study.  Additionally, emergency patients are 
frequently discharged with instructions to follow-up with their regular physicians.  In 
other words, the emergency physician takes care of the immediate issue, but it is the 
patient’s regular physician who continues to monitor the patient and maintain or change 
drug therapy.  The long-term monitoring that a primary care physician performs could 
also explain differences in prescribing decisions between emergency physicians and other 
general practitioners.  The designation of “other” did not have significant impact in either 
the refill or first physician models. 
Region of practice was significant in only one initial model, and became 
insignificant once entered in to the final model.  It was thought that the problems with 
Oxycontin® in Southwestern Virginia in recent years may cause physicians in that region 
to make different decisions than those in urban areas or other rural areas of the 
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Commonwealth.  However, this proved to have almost no impact for the purposes of this 
project.   
Patient characteristics were clearly the most important block of predictors in these 
models.  For all four models, this block of predictors contributed the most to explaining 
the variance.  Physicians were more likely to prescribe for acute and cancer pain when 
compared to CNMU in all four models; however, CNMK was not significantly different 
from CNMU.  In this survey, CNMK was presented as severe osteoarthritis unresponsive 
to acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs).  It is possible that 
if a different diagnosis had been used, that CNMK may have played a larger role.  
Different diagnoses of CNMK were not addressed in this study but could be important.   
A patient’s history of substance abuse was also clearly important to physicians 
when making clinical decisions about prescribing analgesics.  Patients with a history of 
substance abuse and those who currently use drugs recreationally might raise caution and 
decrease a physician’s willingness to prescribe or refill a prescription for a controlled 
substance, with respect to patients with no history of substance abuse.  However, this 
became less important when treating acute or cancer pain as opposed to CNMU, as 
demonstrated by the significant interactions found in the models. 
The variability in package insert information about drug abuse and dependence 
was a main focus of this study.  Variability was measured with three variables:  strength 
of the warning about drug abuse and dependence, the presence of advice in the package 
insert, and definitions of terms used in the insert.  This block of predictors was significant 
in all four models.  Table  6.1  Physician-rated importance of factors in clinical decision 
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making and corresponding regression coefficients illustrates the amount of variance in 
each model explained by package insert variability over and above physician and patient 
characteristics. 
 
Table  6.1  Physician-rated importance of factors in clinical decision making and corresponding 
regression coefficients 
 R2 change  Significance 
Comfort 0.031  <0.001 
Refill 0.023 <0.001 
First physician 0.032 <0.001 
Willingness scale 0.031 <0.001 
 
Between 2.3% and 3.1% of the variance in physician prescribing decisions could 
be explained by the variability in the package insert.  All three predictors were significant 
in all models, except that the presence of advice did not have a significant effect on 
physicians’ decisions to refill a prescription.  The finding that the PDR and package 
insert were ranked among the top three sources consulted for drug abuse and dependence 
information suggests that package insert information on drug abuse and dependence was 
important to physicians.  This further underscores the need for standardization of 
definitions of terms surrounding the issue of drug abuse and dependence and the need for 
more useful information such as clinical advice to be included in package inserts. 
Limitations of Study 
Because the sampling frame for this study was limited to the Commonwealth of 
Virginia, the results may not be generalizeable to a population of United States 
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physicians.  While the Commonwealth of Virginia does have urban, suburban, and rural 
regions, and has areas that have had drug abuse issues, it is difficult to say how closely 
Virginia physicians’ responses would represent those from other states without including 
physicians from other areas. 
 It is unknown whether or not physicians’ responses to questionnaire items 
about prescribing decisions reflect what they would actually do in clinical practice.  
Many variables that may affect physicians’ prescribing decisions, such as the patient’s 
gender, age, ethnicity, and socioeconomic status, were held constant in this survey 
because they were not the focus of this study.  Additionally, many other details present in 
a clinical setting were left out in the interest of creating more concise scenarios.  These 
include lab results and further details about prior treatment received.  Furthermore, a 
physician cannot interact with nor observe behaviors of patients presented on a paper 
questionnaire.  All of these variables may affect decisions that physicians make about 
prescribing. 
 The patients in the case scenarios in this study were all 38 year old 
Caucasian males.  Variables of patient age, race/ethnicity, and gender were kept constant 
because they were not the focus of this study and to maintain a reasonable number of 
variables examined.  It is possible that these variables contribute to a physician’s decision 
to prescribe opioids for pain, and keeping them constant could have decreased the 
variance explained by the models presented here.  However, it was felt defining the 
patient variables was a better option than leaving them unknown and allowing each 
physician to make different assumptions about patient characteristics.  
  
102
Physicians are often considered to be low responders in survey research.  In this 
survey, a response rate of 32.3% was achieved.  While this seems to be low, several of 
the articles reviewed surveyed physicians in a narrower sampling frame.  These included 
a single medical school (Brown et al., 1997), members of a professional organization 
representing only one medical discipline (Greenwald et al., 1999), a small collaborative 
research network (Potter et al., 2001), and a single metropolitan area (Davies et al., 
1997).  People are more likely to respond to a survey that is of interest to them and is 
being conducted by a group to which they feel some sense of loyalty.  Therefore, 
narrowing a sampling frame may increase response rate; however, generalizability of 
results is sacrificed.  With regard to sample size, the database from which the information 
was drawn was not as up to date or accurate as believed, and decreased the reachable 
sample size from 1008 to 846. 
A large national study of physicians from various medical specialties obtained a 
response rate of 27.46% (Turk et al., 1994).  While this study had a lower response rate, 
the sample size and sampling frame allowed the results to be generalized to a larger 
population, assuming that non-response error was not higher than in the other studies.  
Regarding this study, those holding MD and DO degrees are certainly not the only 
professionals with prescribing power. This sampling frame excludes residents and interns 
and those with limited prescribing power such as dentists, nurse practitioners, and 
physicians’ assistants.  These professions were excluded as they do not have full 
autonomy in decision-making and therefore may not be able to answer some of the items 
on the questionnaire. As previously mentioned, this survey sampled physicians in the 
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Commonwealth of Virginia only, so those practitioners who are licensed or residing 
outside of Virginia are not included in the sample.  Thus, the results of this study could 
not be easily generalized to all physicians in the United States.  This project would, 
however, serve as a springboard for a larger, national sample in the future. 
There may be some non-response error in that physicians who responded had an 
earlier year of licensure than did non-responders.  The impact of this on the results is 
unknown, but year of licensure was a significant predictor in all four models.  Based on 
the results of the responders and the difference in licensure year between responders and 
non-responders, the models would err on the side of less prescribing. 
With respect to other physician characteristics, there was no difference between 
responders for region or gender.  Region for non-responders was determined by the 
researcher based on the ZIP code, but was subjectively reported by responders.  It is 
possible that the responding physicians view themselves as being in a different region 
than the researcher would assign based on ZIP code.  Names of non-responding 
physicians were evaluated for likely gender by the researcher.  Any names that were 
gender neutral or foreign names that could not be assigned a gender were considered 
unknown.  It is possible that some non-responders were assigned to the incorrect gender 
category.  Based on the responses for medical discipline, it is apparent that board 
certification does not always reflect a physician’s self-reported specialty.  Medical 
discipline for responders and non-responders was not evaluated. 
Finally, it is possible that some items on the questionnaire were not measuring 
what the researchers intended, or were interpreted differently by respondents.  
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Specifically, three physicians made comments that indicate the item about classifying the 
medication into a CSA schedule was misread as classifying which level of drug control 
should be prescribed for the patient.  It is possible that other physicians also misread this 
item; however, the chi-square analysis performed relating warning strength to physician-
rated schedule indicates that this was not the case. 
The limitations of this study are only minor weaknesses.  Sufficient power was 
achieved in the study as evidenced by the significant findings in the regression models 
and other statistical analyses performed. 
Areas for Future Research 
 The final objective of this dissertation was to provide groundwork for 
future research.  This project contributes to the literature about factors affecting 
physicians’ prescribing decisions by demonstrating that information presented about 
medications can affect their decision-making process.  Surveys of larger size and broader 
sampling frame could support or refute the results found in this study.   
   Three areas of variability in package insert information concerning drug 
abuse and dependence have been identified as significantly affecting the physician’s 
perceptions of the medication.  All three were measured only as nominal variables, 
however, and further research into more specific aspects of warning strength, advice 
given, and definitions relating to terms used in package inserts is warranted.  Physicians 
are not the only health care providers who consult package inserts for drug information.  
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Research about how information is communicated to other health care professionals such 
as nurses and pharmacists would also prove interesting. 
During the course of the completion of this project, the Food and Drug 
Administration (FDA) released statements on changes to the format of package inserts for 
medications.  Research on current package inserts can help to guide regulators in forming 
new guidelines for updated package insert content.  These new package inserts will then 
need to be evaluated.   
Conclusions 
 Many factors were identified as having an affect on physicians’ 
prescribing decisions.  These include physician characteristics such as year of licensure 
and medical discipline, patient characteristics relating to type of pain and substance abuse 
history, and package insert information provided to physicians.  The three areas of 
package insert variability identified in this study were the strength of the warning about 
substance abuse and dependence, the presence of clinical advice given, and the presence 
of definitions of terms used in the package insert.   
 The terms “addiction” and “drug dependence” were generally not viewed 
as interchangeable by physicians.  Drug dependence was more associated with a 
physiological state and addiction with a psychological state.  Sources consulted by 
physicians were varied, with the top three reported as the PDR, package inserts, and 
pharmacists.  This was true for both drug abuse/dependence information and for other 
drug information.  Physicians rated package inserts offering direct advice as more useful 
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than those without any advice.  Advice presented in package inserts was related to patient 
counseling, prescribing to substance abusers, and how to treat withdrawal.   
 Overall, the two studies performed show that: 1) there is high variability in 
drug abuse and dependence information in package inserts, 2) the package insert 
continues to be an important source of drug information for physicians, and 3) package 
insert information can affect a physician’s prescribing decisions.  This could affect the 
quality and safety of patient care.  As the FDA revises the requirements for product 
labeling for new medications, continued evaluation of the package inserts for clarity and 
consistency is imperative.
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A Complete list of package inserts included in Preliminary Study 
 APPENDIX A 
Complete list of package inserts included in Preliminary Study 
 
Generic Name # Entries in database 
Alprazolam 1 
Amphetamine 1 
Buprenorphine 1 
Butalbital 2 
Butorphanol 1 
Caffeine 3 
Chlorazepate 1 
Clonazepam 1 
Codeine 3 
Dexmethylphenidate 1 
Dextroamphetamine 3 
Diazepam 1 
Estazolam 1 
Fentanyl 2 
Hydrocodone 10 
Hydromorphone 1 
Hydroxyzine 2 
Mepiridine 1 
Methamphetamine 1 
Methylphenidate 3 
Modafinil 1 
Morphine 6 
Nalbuphine 1 
Oxycodone 7 
Oxymorphone 1 
Pemoline 1 
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Pentazocine 2 
Pentobarbital 1 
Phendimetrazine 1 
Phenobarbital 2 
Phentermine 2 
Promethazine 1 
Propoxyphene 2 
Sodium Oxybate (GHB) 1 
Tramadol 2 
Zaleplon 1 
Zolpidem 1 
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B Qualitative codes and meanings for Preliminary Study 
 APPENDIX B 
 Qualitative codes and meanings for Preliminary Study 
Code Meaning 
AEAb Abuse is listed in the adverse effects section of the package insert 
AEAd Addiction is listed in the adverse effects section of the package insert 
AEPsD Psychological dependence is listed in the adverse effects section of the 
package insert 
AEWD Withdrawal is listed in the adverse effects section of the package insert 
AntW The package insert contains a warning about administering an antagonist 
CompAbP The abuse potential of the drug is compared to that of a known drug of 
abuse 
CompDep The dependence potential of the drug is compared to that of a known 
drug of abuse 
CompNot The package insert states that the drug is NOT like a particular drug of 
abuse 
CompPhD The physical dependence of the drug is compared to that of a known 
drug of abuse 
CompPsD The psychological dependence of the drug is compared to that of a 
known drug of abuse 
CompSP The chemical structure and pharmacology of the drug are compared with 
a known drug of abuse or a class of drugs with abuse potential 
DTol  The word “tolerance” is discussed, described, or defined 
D/C The package insert contains a warning against abrupt discontinuation of 
the drug 
DChrInt The package insert discusses, describes, or defines chronic intoxication 
DIDOA The package insert discusses drug interactions of the drug with other 
drugs of abuse 
DIDOAN There is no discussion of interactions between the drug and other drugs 
of abuse 
DifAbAd/PhDT There is a statement that abuse zdbgbbg 
DifTolPhD/PsD There is a statement that tolerance and physical dependence are different 
from psychological dependence 
DInWD Withdrawal symptoms in infants are described 
Disc + The drug was discriminated as being similar to another drug of abuse 
DiscHu – The drug was not discriminated by humans as being similar to a known 
drug of abuse 
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DiscHu + The drug was discriminated by humans as being similar to a known drug 
of abuse 
DphD Physical dependence is discussed, described, or defined 
DPsD Psychological dependence is discussed, described, or defined 
DWD Withdrawal is discussed, described, or defined 
DWDdog The package insert indicated that a withdrawal syndrome was found in 
dogs upon discontinuation of the drug 
EqAddDDPsD Addiction, drug dependence, and psychological dependence were 
equated with each other 
EqPsyDAd Psychological dependence was equated with addiction 
ExtUseW There is a warning against extended use of the product 
HospEDrpt The package insert discussed Emergency room hospital visits associated 
with the use of the drug 
HowAb+W The package insert describes or discusses how the drug is abused 
HxDACa The package insert indicates that the drug should be used with caution in 
patients with a history of drug abuse 
HxDACI The package insert states that the use of the drug is contraindicated in 
patients with a history of drug abuse 
HxDAW The package insert indicates that the drug should not be used in patients 
with a history of drug abuse 
Limit The package insert gives a dose limit or time limit for the use of the drug 
MBHF The package insert contains the phrase “May be habit forming” 
NDInWD The package insert states that infants born from mothers using the drug 
experience withdrawal, but symptoms are not described 
NDPhD The term “physical dependence” is used in the package insert, but is not 
otherwise described or defined 
NDPsD The term “psychological dependence is used in the package insert, but is 
not otherwise described or defined. 
NDTol The term “tolerance” is used in the package insert, but is not otherwise 
described or defined 
NDWD The term “withdrawal” is used in the package insert, but is not otherwise 
described or defined 
None The package insert contains no information on drug abuse or dependence 
potential 
NTPW There is a warning against the use of the drug or certain dosage forms of 
the drug in non-tolerant patients 
OnOffse+ The package insert states that the onset and offset of the drug indicate 
that it has increased potential for abuse 
PdD+rab Physical dependence has been seen in dogs and rabbits 
PhD+dog The package insert states that physical dependence occurred in dogs 
PID/C Patient information in the package insert contains a warning against 
abrupt discontinuation of the drug 
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PIDDD Patient information in the package insert discusses, describes, or defines 
“drug dependence” 
PIDTol Patient information in the package insert discusses, describes, or defines 
“tolerance” 
PIDWD Patient information in the package insert discusses, describes, or defines 
“withdrawal” 
PIEqDepAd Patient information in the package insert equated “dependence” with 
“addiction” 
PIHxDACa Patient information in the package insert states that the drug should be 
used with caution in patients with a history of drug abuse 
PIMild The patient information in the package insert was rated to have a mild 
warning about drug abuse potential 
PIMod The patient information in the package insert was rated to have a 
moderate warning about drug abuse potential 
PISch The FDA Controlled Substance Schedusv is given in the patient 
information of the package insert 
PIStBehW The patient information of the package insert contains a warning that the 
drug may cause strange behavior 
PIStrong The patient information of the package insert was rated to have a strong 
warning about drug abuse potential 
PITellMD The patient information of the package insert instructs the patient to tell 
his or her doctor if the patient had a history of drug abuse or was 
currently abusing drugs 
PregW The package insert contains a warning against use in pregnancy 
RareAb The package insert states that abuse of the drug was rare 
RareAd The package insert states that addiction to the drug is rare when used in 
the medical setting appropriately or that iatrogenic addiction to the drug 
is rare 
RareDep The package insert states that “dependence” on the drug is rare 
RareWD The package insert states that withdrawal symptoms rarely occur with 
discontinuation of the drug 
Refer The section dedicated to drug abuse and dependence information refers 
the reader to another section in the package insert 
Restricted The package insert states that the use of the drug is restricted and gives 
information on the restrictions for use 
S&Eun Safety and efficacy data for chronic condition are unavailable 
SA- The drug was not self-administered 
SAP+ The drug was self-administered by primates 
Sch The FDA Controlled Substance Schedule is given in the package insert 
StBehW The package insert states that strange behavior may occur with use of the 
drug 
Steps The package insert gives steps to take in order to prevent abuse or 
diversion of the drug 
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TimePhD The package insert estimates how long it takes for physical dependence 
to occur 
TimeTol The package insert estimates how long it takes to develop tolerance to 
the drug 
TolPtD The package insert defines a “tolerant patient” 
TolPtND The package insert uses the term “tolerant patient” but does not 
otherwise define it 
TrtAdNoRole The package insert asserts that the drug has no role in the treatment of 
drug addiction 
TrtODT/N Treatment of overdose of tolerant and/or non-tolerant patients is 
described 
TrtPhD The package insert gives information on how to treat physical 
dependence on the drug 
TrtTol The package insert gives information on how to treat tolerance 
TrtWD The package insert gives information on to treat withdrawal symptoms 
Wmild The researcher rated the warning about drug abuse potential as mild 
Wmod The researcher rated the warning about drug abuse potential as moderate 
Wstrong The researcher rated the warning about drug abuse potential as strong 
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D Patient case scenarios used in survey 
 APPENDIX D 
 Patient case scenarios used in survey 
Case 1 (No Hx, Cancer pain) 
A 38 year old Caucasian male is presenting to you with increasing pain, a history of 
metastatic cancer, and no longer wishes to receive radiation or chemotherapy. He has no 
history of psychoactive substance abuse. Previously, another physician has prescribed the 
medication associated with the following package insert information: 
 
 
Case 2 (No Hx, CNMP, U) 
A 38 year old Caucasian male presents to you with complaints of lower back pain that 
started about 6 months ago. Diagnostic tests have revealed no structural abnormalities. At 
this time, the cause of the pain is unknown. The patient has no history of psychoactive 
substance abuse.  Previously, another physician has prescribed the medication associated 
with the following package insert information: 
 
 
Case 3 (No Hx, CNMP, K) 
A 38 year old Caucasian male presents to you with increasing hip pain from osteoarthritis 
not relieved by 1000 mg acetaminophen four times daily, nor by 800 mg ibuprofen three 
times daily. He has no history of psychoactive substance abuse.  Previously, another 
physician has prescribed the medication associated with the following package insert 
information: 
 
 
Case 4 (No Hx, Acute) 
A 38 year old Caucasian male follows up with you after being seen in the emergency 
room 3 days ago for a broken ankle. He has no history of psychoactive substance abuse. 
The physician in the emergency room prescribed the drug associated with the following 
package insert information: 
 
 
Case 5 (Past Hx, Cancer pain) 
A 38 year old Caucasian male is presenting to you with increasing pain, a history of 
metastatic cancer, and no longer wishes to receive radiation or chemotherapy. The patient 
has a prior history of psychoactive substance abuse, but has not used in the last 5 years. 
Previously, another physician has prescribed the medication associated with the 
following package insert information:  
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Case 6 (Past Hx, CNMP, U) 
A 38 year old Caucasian male presents to you with complaints of lower back pain that 
started about 6 months ago. Diagnostic tests have revealed no structural abnormalities. At 
this time, the cause of the pain is unknown. The patient has a prior history of 
psychoactive substance abuse, but has not used in the last 5 years.  Previously, another 
physician has prescribed the medication associated with the following package insert 
information: 
 
 
Case 7 (Past Hx, CNMP, K) 
A 38 year old Caucasian male presents to you with increasing hip pain from osteoarthritis 
not relieved by 1000 mg acetaminophen four times daily, nor by 800 mg ibuprofen three 
times daily. The patient has a prior history of psychoactive substance abuse, but has not 
used in the last 5 years.  Previously, another physician has prescribed the medication 
associated with the following package insert information: 
 
 
Case 8 (Past Hx, Acute) 
A 38 year old Caucasian male follows up with you after being seen in the emergency 
room 3 days ago for a broken ankle. The patient has a prior history of psychoactive 
substance abuse, but has not used in the last 5 years. The physician in the emergency 
room prescribed the drug associated with the following package insert information: 
 
  
Case 9 (Current use, Cancer pain) 
A 38 year old Caucasian male is presenting to you with increasing pain, a history of 
metastatic cancer, and no longer wishes to receive radiation or chemotherapy.  He states 
that he occasionally uses psychoactive substances for recreational purposes. Previously, 
another physician has prescribed the medication associated with the following package 
insert information: 
 
 
Case 10 (Current use, CNMP, U) 
A 38 year old Caucasian male presents to you with complaints of lower back pain that 
started about 6 months ago. Diagnostic tests have revealed no structural abnormalities. At 
this time, the cause of the pain is unknown. He states that he occasionally uses 
psychoactive substances for recreational purposes. Previously, another physician has 
prescribed the medication associated with the following package insert information: 
 
 
Case 11 (Current use, CNMP, K) 
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A 38 year old Caucasian male presents to you with increasing hip pain from osteoarthritis 
not relieved by 1000 mg acetaminophen four times daily, nor by 800 mg ibuprofen three 
times daily. He states that he occasionally uses psychoactive substances for recreational 
purposes. Previously, another physician has prescribed the medication associated with the 
following package insert information: 
 
 
Case 12 (Current use, Acute) 
A 38 year old Caucasian male follows up with you after being seen in the emergency 
room 3 days ago for a broken ankle. He states that he occasionally uses psychoactive 
substances for recreational purposes. The physician in the emergency room prescribed the 
drug associated with the following package insert information: 
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E Package insert excerpts used in survey 
 APPENDIX E 
 Package insert excerpts used in survey 
(Strong, Advice, No defs) 
Drug A (PI#1): Severe dependence has occurred with Drug A. Do not prescribe Drug A 
for patients who are suicidal or addiction-prone. Prescribe Drug A with caution for 
patients taking tranquilizers or antidepressant drugs and patients who use alcohol in 
excess. Tell your patients not to exceed the recommended dose and to limit their intake of 
alcohol. Many of the Drug A-related deaths have occurred in patients with previous 
histories of emotional disturbances or suicidal ideation or attempts as well as histories of 
misuse of tranquilizers, alcohol, and other CNS-active drugs.   
 
 
(Not strong, No advice, Defs) 
Drug B (PI#2): As with other drugs in its class, Drug B may produce psychic 
dependence, physical dependence, and tolerance may develop upon repeated 
administration. However, psychic dependence is unlikely to develop when Drug B is used 
for a short time for the treatment of pain. Physical dependence, the condition in which 
continued administration of the drug is required to prevent the appearance of a 
withdrawal syndrome, usually assumes clinically significant proportions only after 
several weeks of continued use, although some mild degree of physical dependence may 
develop after a few days of therapy. Tolerance, in which increasingly large doses are 
required in order to produce the same degree of analgesia, is manifested initially by a 
shortened duration of analgesic effect, and subsequently by decreases in the intensity of 
analgesia. The rate of development of tolerance varies among patients. 
 
 
(Strong, Advice, Defs) 
Drug C (PI#3):  Severe drug dependence and addiction have occurred with Drug C.  
Addiction is a treatable disease characterized by drug-seeking behavior, craving, and 
uncontrolled use. Abuse and addiction are separate and distinct from physical dependence 
and tolerance.  Addiction may not be accompanied by concurrent tolerance and 
symptoms of physical dependence. The converse is also true. In addition, abuse can occur 
in the absence of true addiction and is characterized by misuse for non-medical purposes, 
often in combination with other psychoactive substances. Exercise careful record-keeping 
of prescribing information, including quantity, frequency, and renewal requests. Do not 
prescribe Drug C for patients who are suicidal or addiction-prone. Prescribe Drug C with 
caution for patients taking tranquilizers or antidepressant drugs and patients who use 
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alcohol in excess. Tell your patients not to exceed the recommended dose and to limit 
their intake of alcohol.  
 
 
(Strong, No advice, Defs) 
Drug D (PI#4):  Drug D has a high addiction potential and is subject to criminal 
diversion.  Drug addiction is a disease characterized by compulsive use, use for non-
medical purposes, and continued use despite harm or risk of harm. Drug addiction is 
treatable utilizing a multi-disciplinary approach, but relapse is common.  Addiction is 
separate and distinct from physical dependence and tolerance. Physical dependence, the 
condition in which continued administration of the drug is required to prevent the 
appearance of a withdrawal syndrome, assumes clinically significant proportions only 
after several weeks of continued use, although some mild degree of physical dependence 
may develop after a few days of therapy. Upon abrupt discontinuation of Drug D, 
withdrawal symptoms may occur. These symptoms may include: anxiety, sweating, 
insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, 
piloerection, and rarely hallucinations. 
 
 
(Not strong, Advice, Defs) 
Drug E (PI#5):  Drug E may induce psychic and physical dependence.  Dependence and 
abuse, including drug-seeking behavior and taking illicit actions to obtain the drug are not 
limited to those patients with a prior history of dependence. The risk in patients with 
substance abuse has been observed to be higher.  Drug E is associated with craving and 
tolerance development. Do not discontinue Drug E abruptly, as withdrawal symptoms 
can occur. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, 
nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely 
hallucinations. Should withdrawal symptoms occur, reinstitute therapy with Drug E then 
follow with a gradual, tapered dose reduction of the medication combined with 
symptomatic support. 
 
 
(Strong, No advice, No defs) 
Drug F (PI#6):  Drug F has been associated with severe psychological dependence, 
physical dependence, and tolerance.  However, psychic dependence is unlikely to develop 
when Drug F is used for a short time for the treatment of pain. Withdrawal symptoms can 
occur with abrupt discontinuation. Physical dependence assumes clinically significant 
proportions only after several weeks of continued use, although some mild degree of 
physical dependence may develop after a few days of therapy.   
 
 
(Not strong, Advice, No defs) 
Drug G (PI#7): Psychic dependence, physical dependence, and tolerance may develop 
upon repeated administration of Drug G.  Tell your patients not to exceed the 
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recommended dose and to limit their intake of alcohol.  Should withdrawal symptoms 
occur upon discontinuation, reinstitute therapy with Drug G then follow with a gradual, 
tapered dose reduction of the medication combined with symptomatic support. 
 
 
(Not strong, No advice, No defs) 
Drug H (PI#8):  Like other drugs in its class, Drug H can produce drug dependence and 
therefore has the potential for being abused. Psychic dependence, physical dependence, 
and tolerance may develop upon repeated administration of Drug H. Physical dependence 
assumes clinically significant proportions only after several weeks of continued use, 
although some mild degree of physical dependence may develop after a few days of 
therapy. The rate of development of tolerance varies among patients. 
  
134
F Physician feedback from pilot 
 APPENDIX F 
 Physician feedback from pilot 
Too much reading. 
 
Warning for case 2 is too long. 
 
Put more pity factor in letter to get better response since you aren’t paying us. 
 
Questions for cases look like I’m going to have to fill out a grid. 
 
Packet looks large and intimidating.  Put in letter that there are only 5 questions for each 
case scenario. 
 
Too many cases if you aren’t paying us, or they are too long. 
 
Letter says that you are focusing on package insert information but there are really only a 
couple of questions about it in the questionnaire.  Makes me wonder what you are really 
after. 
 
Make cases and warnings shorter or give fewer.  I probably wouldn’t answer more than 3 
or 4. 
 
Don’t like the font on the cover page. 
 
Will it be in color (printer didn’t have color but file was in color). 
 
Too much about postcard/envelope procedure, and not enough about what to expect from 
the questionnaire itself. 
 
Giving essentially the same three cases twice and only changing the sex makes one of 
your hypotheses obvious, and it has nothing to do with package insert information.  Why 
are you asking this? 
 
More on format of questionnaire in letter because the packet looks like it’s more work 
than it really is. 
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Explain that C-II is highest abuse liability.  I didn’t know what the question was asking 
because I am not familiar with the schedules. 
 
Looks like you are asking about too many factors and variables…is there any way you 
can cut some of these out?  Are they all necessary? 
 
Layout is fine, maybe a booklet would be better if you could cut out some of the 
wordiness; put the letter on letterhead. 
 
Make sure you personally sign all the letters – it makes it more personal and they are 
more likely to fill it out. 
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G Survey cover letter, initial package 
 APPENDIX G 
 Survey cover letter, initial package 
*Note: Original cover letter was on letterhead and formatted to fit onto one page. 
 
 
January 6, 2006 
 
Dear Dr. _________   _____, 
 
I am writing to ask your help with a survey I am conducting for my dissertation research 
project at Virginia Commonwealth University’s School of Pharmacy.  I am interested in 
exploring physicians’ opinions about substance abuse information provided in package 
inserts.   
 
I am contacting a random sample from a registry of physicians in the state of Virginia 
who are in various practice settings.   
 
Enclosed in this packet are the questionnaire, an addressed and stamped envelope for its 
return, and a postcard, also addressed and stamped.  The purpose of this postcard is to 
ensure that all responses are completely anonymous and to prevent repeat mailings. Once 
your post-card is received, your information will be deleted from the mailing list.  The 
questionnaire should be mailed separately from the postcard. 
 
The questionnaire consists of 4 case scenarios with 5 short questions, and then some 
requested information about your views on addiction and dependence, sources you 
consult for information, and general demographics.  There are no correct or incorrect 
answers, as I am interested in your opinions on topics related to drug abuse and 
dependence information.   
 
This survey is voluntary, and you would help me a great deal with my dissertation by 
taking approximately 15 to 20 minutes to fill out and return the enclosed questionnaire.  
If you have any questions or comments about the questionnaire or the survey study, 
please feel free to contact me, either by phone at (804) 828-6096, or by email at 
Hburroughslr@vcu.edu H. 
 
Thank you very much for assisting me with my dissertation research! 
 
Sincerely, 
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Lisa Burroughs Phipps, PharmD/PhD Candidate 
Virginia Commonwealth University 
Department of Pharmacy 
410 N. 12th Street 
PO Box 980533 
Richmond, VA 23298-0533 
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H Follow-up cover letter for survey 
 APPENDIX H 
 Follow-up cover letter for survey 
*Note:  Follow-up cover letter was sent on letterhead and formatted to fit onto one page. 
 
 
February 10, 2006 
 
Dear Dr.     , 
About four weeks ago, you should have received in the mail a questionnaire about drug 
dependence and addiction. To the best of my knowledge, I have not yet received your 
completed questionnaire.  
 
As you may remember from the initial letter, I am writing to ask your help with a survey 
I am conducting for my dissertation research project at Virginia Commonwealth 
University’s School of Pharmacy.  I am interested in exploring physicians’ opinions 
about substance abuse information provided in package inserts. You were randomly 
selected from a registry of physicians in the state of Virginia who are in various practice 
settings.   
 
I have provided you with a replacement questionnaire in case you no longer have the 
original but would like to provide responses. Also enclosed are an addressed and stamped 
envelope for returning the completed questionnaire, and a postcard, also addressed and 
stamped. The purpose of this postcard is to ensure that all responses are completely 
anonymous and to prevent repeat mailings. Once your post-card is received, your 
information will be deleted from the mailing list.  The questionnaire should be mailed 
separately from the postcard.  This will ensure that responses are anonymous. 
 
The questionnaire consists of 4 case scenarios with 5 short questions, and then some 
requested information about your views on addiction and dependence, sources you 
consult for information, and general demographics.  There are no correct or incorrect 
answers, as I am interested in your opinions on topics related to drug abuse and 
dependence information.   
 
This survey is voluntary, and you would help me a great deal with my dissertation by 
taking approximately 15 to 20 minutes to fill out and return the enclosed questionnaire.  
If you have any questions or comments about the questionnaire or the survey study, 
please feel free to contact me, either by phone at (804) 828-6096, or by email at 
Hburroughslr@vcu.edu H. 
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Thank you very much for assisting me with my dissertation research! 
 
Sincerely, 
 
 
 
Lisa Burroughs Phipps, PharmD/PhD Candidate 
Virginia Commonwealth University 
Department of Pharmacy 
410 N. 12th Street 
PO Box 980533 
Richmond, VA 23298-0533 
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I Codebook for SPSS Analysis 
 APPENDIX I 
 Codebook for SPSS Analysis 
SPSS Code Variable Values 
Resp# Respondant # 100-2414 
QV Questionnaire version 1-24 
Case# Patient case  1-12 
PI# Package insert excerpt 1-8 
PIStr Strength of warning  0=not strong; 1=strong 
PIAdv Advice in package insert 0=no advice; 1=advice present 
PIDefs Definitions in package insert 0=no definitions; 
1=definitions given 
PtPain Type of pain 1=Acute 
2=Cancer 
3=Chronic, nonmalignant, known 
etiology (CNMK) 
4=Chronic, nonmalignant, unknown 
etiology (CNMU) 
PtHx Patient substance abuse history 1=No history of substance abuse 
2=Prior history of substance abuse 
3=Current recreational use 
Comf Comfort level with prior 
physician’s prescription 
Ref Refill likelihood 
Rx Prescribe if first physician? 
Useful Insert information useful? 
For questions following scenarios: 
0=Not at all 
1=Not very 
2=Somewhat 
3=Definitely 
Sch Physician-rated schedule for drug 2=C-II 
3=C-III 
4=C-IV 
5=C-V 
6=not controlled 
SrManD Source manufacturer for DDAD  
SrMan Source manufacturer for other info 
SrDICD Source drug info ctr for DDAD 
SrDIC Source drug info ctr for other info 
SrIntD Source internet for DDAD 
SrInt Source internet for other info 
SrPID Source package insert for DDAD 
For sources consulted for drug abuse 
and dependence information 
(DDAD), and for other information: 
0=Never 
1=Yearly 
2=Monthly 
3=Weekly 
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SrPI Source package insert for other info 
SrPDAD Source PDA for DDAD 
SrPDA Source PDA for other info 
SrRPhD Source pharmacist for DDAD 
SrRPH Source pharmacist for other info 
SrPDRD Source PDR for DDAD 
SrPDR Source PDR for other info 
SrOthD Other sources used for DDAD 
SrOth Other sources used for other info 
4=Daily 
FacCSA Importance of CSA schedule 
FacDef Importance of definitions in insert 
FacHx Importance of patient’s substance 
abuse history 
FacAdv Importance of advice in insert 
FacPain Importance of type of pain being 
treated 
FacWarn Importance of package insert 
warning strength 
Rating importance of factors in 
clinical decision making: 
0=Not at all important 
1=Somewhat unimportant 
2=Somewhat important 
3=Very important 
DDAb 
DDCr 
DDDSB 
DDPhyD 
DDPsD 
DDTol 
DDWD 
Abuse 
Craving 
Drug Seeking Behavior 
Physical Dependence 
Psychological Dependence 
Tolerance 
Withdrawal 
Necessary for Drug Dependence: 
0=no 
1=yes 
AddAb 
AddCr 
AddDSB 
AddPhyD 
AddPsD 
AddTol 
AddWD 
Abuse 
Craving 
Drug Seeking Behavior 
Physical Dependence 
Psych Dependence 
Tolerance 
Withdrawal 
Necessary for Addiction: 
0=no 
1=yes 
MDGender Physician Gender 0=Female 
1=Male 
MDLiscYr Physician Year of initial licensure 1940-2005 
MDSpec Physician Specialty Entered as text 
MDHxPer Estimated percent of patients with 
known substance abuse history 
0-100 
MDRegion Physician practice region 1=Northern 
2=Western 
3=Central 
4=Tidewater 
5=Southern 
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6=Southwestern 
7=Northern Neck 
8=Eastern Shore 
MDLiscYrMV Licensure year with median 
inserted for missing variables 
1940-2005 
MDhXPerMV Estimated percent of patients with 
known substance abuse history with 
median inserted for missing 
variables 
0-100 
DumPnAcute Indicator for acute pain 0=not acute pain 
1=acute pain 
DumPnCancer Indicator for cancer pain 0=not cancer pain 
1=cancer pain 
DumPnCNMK Indicator for CNMK 0=not CNMK 
1=CNMK 
DumHxPast Indicator for past substance abuse 
history 
0=not a past history 
1=past history 
DumHxCurr Indicator for current substance use 0=not a current user 
1=current user 
MDSpecNum Numerical category assignment for 
medical specialty 
0=Emergency medicine 
1=Family practice 
2=Internal medicine 
3=Other 
DumMDSpecFP Indicator for family practice 0=not family practice 
1=family practice 
DumMDSpecIM Indicator for internal medicine 0=not internal medicine 
1=internal medicine 
DumMDSpecOth Indicator for other specialty 0=not “other” specialty 
1=other specialty 
NewRegion Collapsed category assignments for 
practice region 
0=Southwestern 
1=Northern, Central, or Tidewater 
(Urban) 
2=Western, Southern, Northern 
Neck, or Eastern Shore (Other rural) 
DumReg1 Indicator for urban region 0=not urban 
1=urban 
DumReg2 Indicator for other rural region 0=not “other rural” region 
1=other rural region 
MDratedStr Physician rated strength of package 
insert warning 
0=not C-II 
1=C-II 
DumUseful Indicator for usefulness of package 
insert information 
0=not useful (not at all or not very) 
1=useful (somewhat or definitely) 
DVScale Willingness to prescribe Score=Comfort+Refill+Rx 
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IntAcPast Acute pain, Past history 
IntAcCurr Acute pain, Current use 
IntCanPast Cancer pain, Past history 
IntCanCurr Cancer pain, Current use 
IntCNMKPast CNMK, Past history 
IntCNMKCurr CNMK, Current use 
Interaction terms are products for 
indicator variables of pain type and 
substance abuse history.  Example: 
Acute*Past 
0=not acute pain and past history 
1=acute pain and past history 
IntStrPast Strong warning, past history 
IntStrCurr Strong warning, current use 
Interaction terms are products for 
indicator variables warning strength 
and substance abuse history 
IntStrAc Strong warning, acute pain 
IntStrCan Strong warning, cancer pain 
IntStrCNMK Strong warning, CNMK 
Interaction terms are products for 
indicator variables warning strength 
and pain type 
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J Respondent comments 
 APPENDIX J 
 Respondent comments 
Note:  Most respondents did not make additional comments. Comments that were made 
are quoted below. 
 
 
“Good luck!”  (Four respondents wrote this) 
 
 
“Good luck on your research! ☺” 
 
 
“As previously noted, the package inserts are given to the patient and seldom carried by 
the patient for the prescribing physicin’s review.  Physicians are familiar with most all 
analgesic medications and controlled substances with regard to their potential for 
dependance/abuse.  Decisions regarding what strength of pain medication to use is 
multifactorial.  Your first case scenario did not state what type metastatic cancer or what 
type pain the patient was experiencing or anticipated length of life expectancy.  Scneario 
3 involved an ankle fracture which after splinted should not be extremely painful after 3 
days; whereas arthritis (scenario 4) can be extremely painful depending on the type 
arthritis and degree of swelling.  Best wishes to you!” 
 
 
“1) History of drug abuse/dependence should not deter a physician from treating acute 
pain that is moderately severe or greater.  More appropriate would be smaller # 
pills/prescription.  Close follow-up, planned duration of treatment, etc.”   2)  For patients 
with chronic pain, use of contracts between physician and patient can be helpful.” 
 
 
“I tried to answer as if I were back in private practice.  As an ER doc, I’m LESS likely to 
rx highly controlled, MORE likely to be faced with DSB, and more likely to alleviate 
suffering short-term (visit only) rather than Rx’ing meds that should be managed by a 1° 
MD.  I don’t write controlleds for chronic pain except terminal patients and will point to 
package inserts in my explanation to patients.” 
 
“- Package inserts often based on initial FDA studies and not reflections of general 
clinical practice.   – They are useful for initial start-up use and occasional to look up side 
effects, warnings (preg risks, etc).  I find I use them less and less.   – The scenarios are 
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hard to judge as I need more details (lots more) and need to know the particular drug to 
really be able to make any decisions.” 
“I am an internist who practices in the field of addiction treatment, therefore tolerance 
and physical dependence do not equal your definitions to me.  Drug abuse = misuse.  
Drug dependence = addiction” 
 
 
“I would be interested in reading a copy of your research results if available. Thanks.”  
(Note: this physician signed the comment but it is not readable!) 
 
 
“Each patient is different.  Each doctor is different.  Each pain is different.  Package 
inserts are helpful re: pharmacokinetics but worthless re: pharmacodynamics.  Your 
survey falls into the realm of not enough depth to be helpful but enough data to be 
dangerous!” 
 
 
“Good luck with your dissertation – would love to know your interpretation of data and 
conclusions – let us know if you can.” (Note: this note was unsigned) 
 
 
“Good luck, Lisa, and don’t forget to have fun.” 
 
 
“Regarding the question of drug dependence, neither physical or psychological 
dependence are necessary, but each are sufficient to make the diagnosis of dependence.” 
 
 
“The DEA definitions of drug dependency are very scant and need to be simplified, so 
they can be useful to clinicians.  Your definitions are a lot more detailed and useful 
alerting the physicians to the very real concerns of dependence for commonly prescribed 
drugs.” 
 
 
“The scenarios presented are helpful. There are many situations not discussed that may or 
may not be deserving of study.  These are individuals with criminal behavior, untreated 
psychiatric states, etc.  These should be referred to the drug abuse clinics for thorough 
examination/treatment.  Thank you for the opportunity to be of service.” 
 
 
“I do not prescribe controlled substances in A/I practice, but your questions made me 
realize I how much I encounter this problem although it raises suspicion on some phone 
calls of denied meds.  Good luck.” 
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“In ER practice prescription of drugs with potential for addiction/dependence is quite 
limited.  When they are prescribed for pain only small amounts are usually prescribed.” 
 
 
“I do not prescribe pain Rx to any sig °.  I refer those people to pain tx ctr.” 
 
 
“Prescription fraud laws should be tougher!” 
 
 
“Your questions were good but don’t cover all situations – for example, depending on the 
type of remote history of drug abuse, one might consider a short course of narcotics e.g. 
2-3 days for someone with a broken ankle…for people with chronic pain, one would not 
do this.  Good luck with your dissertation!” 
 
 
“Thank you, Lisa, for exploring these issues!  Please go deeply into this whole issue.  
Adequate pain control in our institutions/hospice programs/at home…in 
brig…everywhere, is a big, big issue for us all.  Try to separate the so-called ‘moral 
issues’ from the behavioral and factual issues as much as possible.  Good luck w/ your 
degree!” 
 
 
“The package insert questions may be skewed by the fact that in my practice I rarely see 
package inserts.” 
 
 
“Narcotics contract and log sheets have been real helpful to help in dealing with chronic 
use of controlled substances for pain, etc.” 
 
 
“The choice to prescribe the same med as presented in the case may have been made 
easier if the patient had previously experienced relief while on this pill.  For instance, in 
case #3, if that had been included, I’d have  √ed  definitely.” (Note: Case #3 for this 
questionnaire was cancer pain, prior history, drug A) 
 
 
“Hope this has been helpful.  Pain (chronic) management is a very complex assignment.  
Good luck with this project.” 
 
 
“1.  I will prescribe a non Class II and class III analgesic if the clinical condition is 
known and duration of use will be for less than 2 weeks.  2.  For any patient presenting 
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with a pain issue, a full work-up to pinpoint the etiology is first and foremost.  Given no 
dx – I will consider referral to a pain specialist (this step occurs after a rigorous search 
(work-up) for the etiology of the pain.  3.  In your 1st case, a hx of metastatic CA is not 
enough.  The CA must be proven and documentation in my hands.  Then I would 
prescribe but referer to a pain specialist ASAP and not manage the patient’s pain state.”  
(Note: Case #1 for this questionnaire was cancer pain, no history, Drug A) 
 
 
“My approach is to always refer pain syndromes to a pain specialist if there is no specific 
clear reason of pain.  I will treat self-limited pain associated with a specific clear dx that 
would be self-limited.  Any cancer-associated pain management is referred to heme/onc.  
Palliative terminal pain management is coordinated with Hospice.  Chronic pain 
syndromes are always referred to a chronic pain management group or clinic.” 
 
 
“My patients are all institutionalized due to mental retardation – hence drug/substance 
abuse is very rare.  I’m not too familiar with the Controlled Substance Schedule, but 
know from experience the degree of potential dependence and addiction associated with 
the limited number of analgesics I use.  Drugs of abuse often make people feel better – at 
least in the short-term – than psychotropic drugs.  If from a public health perspective our 
society is in some ways ‘toxic’ to our psychological well being (lack of a sense of 
belonging, lack of community, alienation, lack of social cohesions), then drug abuse is a 
symptom not only of an individual’s psychic ‘discomfort,’ but of the society’s ‘sickness.’  
See Richard Wilkinson’s ‘Unhealthy Societies.’” 
 
 
“ – Pain should be treated appropriately.  – Know your patient (in practice for 1 month or 
20 years, etc).  – Document reasons (objective) for pain evaluation.  – Document benefits 
of therapy.  – Follow up and careful monitoring.  – Get family involved.  – Etc etc.” 
 
 
“I avoid even narcotic cough medications when possible.” 
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K Statistics for regression models 
 APPENDIX K 
 Statistics for regression models 
For Comfort model: 
Predictor Variable B Std error p-value
Physician gender  -0.093 0.066 0.157
Licensure year  0.011 0.002 <0.001
% pts with history  0.000 0.002 0.908
Practice region Urban 0.091 0.091 0.317
 Other rural 0.166 0.103 0.106
Medical discipline Family practice -0.335 0.081 <0.001
 Internal medicine -0.342 0.082 <0.001
 Other -0.306 0.108 0.005
Type of pain Acute 1.125 0.129 <0.001
 Cancer 1.437 0.126 <0.001
 CNMK 0.243 0.134 0.070
History of abuse Past -0.423 0.127 0.001
 Current -0.500 0.132 <0.001
Warning strength  -0.270 0.053 <0.001
Advice present  -0.169 0.053 0.002
Definitions given  -0.196 0.053 <0.001
Interaction terms Acute*Past -0.355 0.182 0.051
Pain*History Acute*Current 0.198 0.183 0.280
 Cancer*Past 0.414 0.183 0.024
 Cancer*Current 0.364 0.183 0.047
 CNMK*Past 0.313 0.184 0.088
 CNMK*Current 0.086 0.188 0.649
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For Refill model: 
Predictor Variable B Std error p-value
Physician gender  0.040 0.065 0.535
Licensure year  0.011 0.002 0.000
% pts with history  -0.002 0.002 0.287
Practice region Urban 0.104 0.090 0.251
 Other rural 0.147 0.102 0.150
Medical discipline Family practice -0.177 0.080 0.027
 Internal medicine -0.161 0.081 0.049
 Other -0.193 0.107 0.072
Type of pain Acute 0.901 0.128 0.000
 Cancer 1.585 0.124 0.000
 CNMK 0.290 0.133 0.029
History of abuse Past -0.281 0.125 0.025
 Current -0.374 0.131 0.004
Warning strength  -0.252 0.052 0.000
Advice present  -0.103 0.053 0.051
Definitions given  -0.153 0.052 0.003
Interaction terms Acute*Past -0.435 0.180 0.016
Pain*History Acute*Current -0.113 0.182 0.533
 Cancer*Past 0.244 0.181 0.179
 Cancer*Current 0.176 0.181 0.333
 CNMK*Past 0.133 0.182 0.466
 CNMK*Current 0.001 0.186 0.997
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For 1st physician model: 
Predictor Variable B Std error p-value
Physician gender  -0.081 0.066 0.217
Licensure year  0.012 0.002 <0.001
% pts with history  0.002 0.002 0.195
Practice region Urban 0.132 0.091 0.148
 Other rural 0.231 0.103 0.026
Medical discipline Family practice -0.181 0.081 0.025
 Internal medicine -0.239 0.082 0.004
 Other -0.205 0.109 0.061
Type of pain Acute 1.143 0.129 <0.001
 Cancer 1.389 0.126 <0.001
 CNMK 0.181 0.134 0.178
History of abuse Past -0.370 0.127 0.004
 Current -0.395 0.133 0.003
Warning strength  -0.276 0.053 <0.001
Advice present  -0.175 0.053 0.001
Definitions given  -0.175 0.053 0.001
Interaction terms Acute*Past -0.507 0.183 0.006
Pain*History Acute*Current -0.051 0.184 0.781
 Cancer*Past 0.376 0.183 0.041
 Cancer*Current 0.273 0.184 0.137
 CNMK*Past 0.224 0.184 0.224
 CNMK*Current -0.019 0.188 0.920
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For Willingness scale model: 
Predictor Variable B Std error p-value
Physician gender  -0.134 0.179 0.453
Licensure year  0.034 0.006 <0.001
% pts with history  <0.001 0.005 0.962
Practice region Urban 0.327 0.249 0.189
 Other rural 0.546 0.281 0.052
Medical discipline Family practice -0.693 0.220 0.002
 Internal medicine -0.742 0.225 0.001
 Other -0.710 0.297 0.017
Type of pain Acute 3.170 0.351 <0.001
 Cancer 4.411 0.343 <0.001
 CNMK 0.713 0.365 0.051
History of abuse Past -1.075 0.346 0.002
 Current -1.269 0.362 <0.001
Warning strength  -0.797 0.145 <0.001
Advice present  -0.448 0.146 0.002
Definitions given  -0.524 0.144 <0.001
Interaction terms Acute*Past -1.298 0.497 0.009
Pain*History Acute*Current 0.025 0.501 0.960
 Cancer*Past 1.034 0.499 0.039
 Cancer*Current 0.816 0.500 0.103
 CNMK*Past 0.670 0.501 0.181
 CNMK*Current 0.067 0.512 0.896
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